var title_f15_48_16128="Esophageal candidiasis";
var content_f15_48_16128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sameer Saini, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16128=[""].join("\n");
var outline_f15_48_16128=null;
var title_f15_48_16129="Tenoxicam: International drug information";
var content_f15_48_16129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenoxicam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1980234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alganex (SE);",
"     </li>",
"     <li>",
"      Arthirinal (CY);",
"     </li>",
"     <li>",
"      Artriunic (ES);",
"     </li>",
"     <li>",
"      Artrocam (CZ, HR);",
"     </li>",
"     <li>",
"      Bioreucam (PT);",
"     </li>",
"     <li>",
"      Calibral (PT);",
"     </li>",
"     <li>",
"      Dolmen (IT);",
"     </li>",
"     <li>",
"      Doxican (PT);",
"     </li>",
"     <li>",
"      Legil (BR);",
"     </li>",
"     <li>",
"      Liman (AT, DE);",
"     </li>",
"     <li>",
"      Mefenix (AR);",
"     </li>",
"     <li>",
"      Mobiflex (GB, IE);",
"     </li>",
"     <li>",
"      Reutenox (ES);",
"     </li>",
"     <li>",
"      Rexalgan (IT);",
"     </li>",
"     <li>",
"      Tenoxen (BR);",
"     </li>",
"     <li>",
"      Texicam (AR);",
"     </li>",
"     <li>",
"      Tilatil (AR, BR);",
"     </li>",
"     <li>",
"      Tilcotil (AT, AU, BE, CH, CZ, DE, DK, ES, FI, FR, HU, IT, LU, MX, NL, PT);",
"     </li>",
"     <li>",
"      Tilcotil &rdquo;Roche&rdquo; (HU);",
"     </li>",
"     <li>",
"      Tobitil (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of rheumatoid arthritis and osteoarthritis; short-term management of acute musculoskeletal disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: 20 mg daily for 7 days; maximum 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     I.M., I.V.: 20 mg daily for 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, powder for reconstitution: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10436 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16129=[""].join("\n");
var outline_f15_48_16129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980234\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980229\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980232\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980228\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821065\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980231\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10436|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16130="Stable UCL";
var content_f15_48_16130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulnar collateral ligament: Stable",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An abduction stress placed upon the ulnar collateral ligament in this photograph reveals a stable endpoint without increased motion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16130=[""].join("\n");
var outline_f15_48_16130=null;
var title_f15_48_16131="Glucagon: Patient drug information";
var content_f15_48_16131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glucagon: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     see \"Glucagon: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     see \"Glucagon: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      GlucaGen&reg;;",
"     </li>",
"     <li>",
"      GlucaGen&reg; Diagnostic Kit;",
"     </li>",
"     <li>",
"      GlucaGen&reg; HypoKit&reg;;",
"     </li>",
"     <li>",
"      Glucagon Emergency Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14733086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      GlucaGen&reg;;",
"     </li>",
"     <li>",
"      GlucaGen&reg; HypoKit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to quiet the GI (gastrointestinal) tract so it may be x-rayed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by beta blockers and calcium channel blockers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702206",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glucagon or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11376 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16131=[""].join("\n");
var outline_f15_48_16131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176479\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14733086\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013701\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013700\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013704\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013705\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013707\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013703\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013709\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=related_link\">",
"      Glucagon: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=related_link\">",
"      Glucagon: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16132="Pyrazinamide: Pediatric drug information";
var content_f15_48_16132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrazinamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"    see \"Pyrazinamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/39/29300?source=see_link\">",
"    see \"Pyrazinamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tebrazid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"      see \"Pyrazinamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Tuberculosis, treatment:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen. Treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children &lt; 40 kg, and Adolescents &le;14 years and &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Non-HIV patients (CDC, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Daily therapy: 15-30 mg/kg/dose (maximum: 2 g/dose) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Directly observed therapy (DOT): 50 mg/kg/dose (maximum: 2 g/dose) twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HIV-exposed/infected patients: (CDC, 2009): Daily therapy: 20-40 mg/kg/dose once daily (maximum: 2 g/day) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Suggested dosing based on lean body weight (Blumberg, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 1500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 2000 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twice weekly directly observed therapy (DOT):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 3000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 4000 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 times/week DOT:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 1500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 2500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 3000 mg (maximum dose regardless of weight)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F12729877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F ).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of",
"     <i>",
"      Mycobacterium",
"     </i>",
"     tuberculosis infection in combination with other antituberculosis agents (FDA approved in children and adults); especially useful in disseminated and meningeal tuberculosis; CDC currently recommends a 3 or 4 multidrug regimen which includes pyrazinamide, rifampin, INH, and at times ethambutol or streptomycin for the treatment of tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acne, angioedema (rare), anticoagulant effect, dysuria, fever, gout, hepatotoxicity,  interstitial nephritis, itching, photosensitivity, porphyria, rash, sideroblastic anemia, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrazinamide or any component; severe hepatic damage",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal failure, gout, diabetes mellitus, patients receiving concurrent medications associated with liver injury (particularly with rifampin), or in patients with a history of alcoholism",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related hepatotoxicity ranging from transient ALT/AST elevations to jaundice, hepatitis, and/or liver atrophy (rare) has occurred; the 2-month rifampin-pyrazinamide regimen for the treatment of latent tuberculosis infection (LTBI) has been associated with severe and fatal liver injuries; incidence increased with pyrazinamide doses &gt;30 mg/kg/day. The IDSA and CDC recommend that the 2-month rifampin-pyrazinamide regimen should not generally be used in patients with LTBI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Pyrazinamide may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: Pyrazinamide may enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13375012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Although not recommended as the initial treatment regimen, the use of pyrazinamide during pregnancy is recommended by The World Health Organization (Blumberg, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, serum uric acid",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Converted to pyrazinoic acid in susceptible strains of",
"     <i>",
"      Mycobacterium",
"     </i>",
"     which lowers the pH of the environment",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed into body tissues and fluids including the liver, lung, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 9-10 hours, prolonged with reduced renal or hepatic function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (4% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/39/29300?source=see_link\">",
"      see \"Pyrazinamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fatigue, weakness, nausea, abdominal pain, jaundice, vomiting, or joint pain and swelling occur. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F215757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 100 mg/mL oral suspension may be made with tablets. Crush two-hundred pyrazinamide 500 mg tablets and mix with a suspension containing 500 mL  methylcellulose 1% and 500 mL simple syrup. Add to this a suspension containing one-hundred forty crushed pyrazinamide tablets in 350 mL methylcellulose 1% and 350 mL simple syrup to make 1.7 L suspension. Label \"shake well\" and \"refrigerate\". Stable for 60 days refrigerated (preferred) and 45 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Peritre SP, &ldquo;Stability of Pyrazinamide in Two Suspensions,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1995, 52(14):1558-60.",
"     <span class=\"pubmed-id\">",
"      7552903",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, \"American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Treatment of Tuberculosis,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(11):785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/2124671/pubmed\" id=\"2124671\" target=\"_blank\">",
"        2124671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations - United States, 2001,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2001, 50(34):733-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16132/abstract-text/11787580/pubmed\" id=\"11787580\" target=\"_blank\">",
"        11787580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12751 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16132=[""].join("\n");
var outline_f15_48_16132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049590\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049584\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215752\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215737\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12729877\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049592\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215814\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049596\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049583\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049582\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299964\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215746\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215748\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049589\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049595\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049588\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215757\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12751|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=related_link\">",
"      Pyrazinamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/39/29300?source=related_link\">",
"      Pyrazinamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16133="Prurigo nodularis 4";
var content_f15_48_16133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16133=[""].join("\n");
var outline_f15_48_16133=null;
var title_f15_48_16134="Tolazamide: Drug information";
var content_f15_48_16134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolazamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/44/28356?source=see_link\">",
"    see \"Tolazamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral (doses &gt;500 mg/day should be given in 2 divided doses):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     100-250 mg/day with breakfast or the first main meal of the day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fasting blood sugar &lt;200 mg/dL: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fasting blood sugar &gt;200 mg/dL: 250 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient is malnourished, underweight, elderly, or not eating properly: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjustment/titration:",
"     </i>",
"     Increase in increments of 100-250 mg/day at weekly intervals to response; maximum daily dose: 1 g (doses &gt;1 g/day are not likely to improve control)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from insulin to tolazamide:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;20 units day = 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21-&lt;40 units/day = 250 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;40 units/day = 250 mg/day and 50% of insulin dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conservative initial and maintenance doses are recommended because tolazamide is metabolized to active metabolites, which are eliminated in the urine.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conservative initial and maintenance doses and careful monitoring of blood glucose are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet for the management of mild-to-moderately severe, stable, type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TOLAZamide may be confused with TOLBUTamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tolinase&reg; may be confused with Orinase",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, malaise, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Maculopapular eruptions, morbilliform eruptions, photosensitivity, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reaction, hypoglycemia, hyponatremia, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric fullness, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, pancytopenia, porphyria cutanea tarda, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuretic effect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolazamide, sulfonylureas, or any component of the formulation; type 1 diabetes mellitus (insulin dependent, IDDM) therapy; diabetic ketoacidosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonylurea allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F228786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (possible disulfiram-like reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of tolazamide. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, tolazamide is classified as pregnancy category C. Severe hypoglycemia lasting 4-10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. The manufacturer recommends if tolazamide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5655337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tolazamide is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F228777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TOLAZamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $152.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $230.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia (fatigue, sweating, numbness of extremities); blood glucose; hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F228770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Desumide (TW);",
"     </li>",
"     <li>",
"      Diabewas (IT);",
"     </li>",
"     <li>",
"      Esulin (TW);",
"     </li>",
"     <li>",
"      Huacose (TW);",
"     </li>",
"     <li>",
"      Tolanase (GB);",
"     </li>",
"     <li>",
"      Tolinase (AE, BH, CY, EG, ES, IL, IQ, IR, JO, KW, LB, LY, NL, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of hypoglycemic effect: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak hypoglycemic effect: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to 5 metabolites (activity 0% to 70%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (85%); feces (7%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-Onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/10639304/pubmed\" id=\"10639304\" target=\"_blank\">",
"        10639304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rull JH and Lennhoff M, &ldquo;Prolonged and Recurrent Tolazamide-Induced Hypoglycemia,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1967, 16(5):352-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/6022563/pubmed\" id=\"6022563\" target=\"_blank\">",
"        6022563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seger D, &ldquo;Toxic Emergencies of Endocrine and Metabolic Therapeutic Agents,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1988, 6(6):527-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/48/16134/abstract-text/3065405/pubmed\" id=\"3065405\" target=\"_blank\">",
"        3065405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10002 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16134=[""].join("\n");
var outline_f15_48_16134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228808\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228793\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228794\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228795\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228796\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228769\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228754\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228772\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228812\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228806\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228775\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228758\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300152\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228763\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228786\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228764\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228797\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5655337\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228777\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228767\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228770\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228779\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228757\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228774\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10002\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10002|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/44/28356?source=related_link\">",
"      Tolazamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16135="Metyrapone stimulation tests";
var content_f15_48_16135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metyrapone stimulation tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16135/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/48/16135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test is based upon the principle that decreasing serum cortisol concentrations is expected to produce an increase in corticotropin (ACTH) secretion. The utilization of the metyrapone test has become less frequent as a result of the larger availability of plasma ACTH assays. The limited accessibility to metyrapone in certain countries as well as the limited number of clinical laboratories who have maintained the urinary 17-OHCS and serum 11-deoxycortisol tests have also further limited the use of the metyrapone tests. The insulin tolerance test is the gold-standard to evaluate the integrity of the hypothalamic-pituitary axis, but it requires close surveillance with inherent risks of severe hypoglycemia; it also has specific contraindications in patients with epilepsy and coronary disease and high costs, so other alternative tests have been developed. The metyrapone test is considered to be a sensitive alternative test to evaluate the ACTH reserve and it is a useful clinical research tool to evaluate the response of the hypothalamic-pituitary-adrenal axis in various pathologies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    stimulation test protocols and interpretation will be reviewed here. Other tests to evaluate the hypothalamic-pituitary-adrenal axis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=see_link\">",
"     \"Insulin-induced hypoglycemia test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    blocks the conversion of 11-deoxycortisol to cortisol by CYP11B1 (11-beta-hydroxylase, P-450c11), the last step in the synthesis of cortisol, and induces a rapid fall of cortisol and an increase of 11-deoxycortisol in serum (",
"    <a class=\"graphic graphic_figure graphicRef56413 \" href=\"UTD.htm?42/12/43212\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81918 \" href=\"UTD.htm?9/7/9342\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because it is essentially devoid of glucocorticoid activity, 11-deoxycortisol does not inhibit ACTH secretion. Thus, in healthy individuals, the fall in serum cortisol concentrations leads sequentially to increases in ACTH secretion, adrenal steroidogenesis, and the secretion of cortisol precursors, in particular, 11-deoxycortisol, the substrate of CYP11B1, which can be measured by radioimmunoassay, HPLC, or in urine as a 17-hydroxycorticosteroid (17-OHCS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in serum 11-deoxycortisol concentrations or in urinary 17-OHCS excretion provides an index of the increase in ACTH release; a failure of these values to rise can indicate either ACTH deficiency or primary adrenal disease. Thus, if the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test is abnormal, the ability of the adrenal gland to respond to exogenous ACTH must be assessed to distinguish between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the detection of ACTH deficiency, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test can also be used in the evaluation of patients with ACTH-dependent Cushing's syndrome. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Response in ACTH-dependent Cushing's syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test can be performed as an overnight single-dose test or as a two- or three-day test. It cannot be performed in a patient who is taking any glucocorticoid. Metyrapone is currently available in North America through its new distributor HRA Pharma (Paris, France) via its specialty pharmacy Direct Success Inc. with order forms available on the",
"    <a class=\"external\" href=\"file://www.metopirone.us/\">",
"     web",
"    </a>",
"    or by phone at 1-855-674-7663; order forms can be faxed to 1-855-674-6767.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The two-day test is used primarily in the differential diagnosis of hypercortisolism.",
"     </li>",
"     <li>",
"      The three-day test is used mainly for the evaluation of adrenal insufficiency.",
"     </li>",
"     <li>",
"      In both tests, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      is given for one day.",
"     </li>",
"     <li>",
"      The single-dose overnight test can be used for both indications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    administration may result in hypotension, nausea, and vomiting in patients with adrenal insufficiency; as a result, the two- and three-day tests should not be performed outside of the hospital in patients suspected of having this disorder. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Drug side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Standard three-day metyrapone test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three-day test is begun by obtaining a baseline 24-hour urine collection, usually beginning at 8 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .) Immediately after completing this collection, the patient begins taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    (750 mg orally every four hours for six doses) with a glass of milk or a small snack to minimize gastrointestinal symptoms.",
"   </p>",
"   <p>",
"    Subsequent 24-hour urine specimens are collected the day of and the day after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    administration for measurement of urinary 17-OHCS and creatinine excretion. Serum 11-deoxycortisol, cortisol, and plasma ACTH can also be measured four hours after the last dose of metyrapone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in serum 11-deoxycortisol is used as a criterion of response as in the single-dose overnight test (see below). Measuring serum cortisol and plasma ACTH is important, as a fall in serum cortisol confirms the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    -induced biosynthetic blockade, and an increase in plasma ACTH confirms that the changes in steroid levels are ACTH-dependent.",
"   </p>",
"   <p>",
"    A normal response to the standard three-day test consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A two- to threefold increase above the baseline 24-hour urinary 17-OHCS excretion on either the day of or, more often, the day after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      administration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The serum cortisol concentration should decrease to less than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      The plasma ACTH concentration should exceed 75",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      with a mean of about 200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      four hours after the last",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      dose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=see_link\">",
"       \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increase in serum 11-deoxycortisol to 7 to 22",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (210 to 660",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      or more at 8 AM, four hours after the last dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Two-day metyrapone test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two-day test is a slight variation on the standard three-day test: 24-hour urine and 8 AM blood specimens are collected during (urine) and at the end of (blood) a baseline day and during and at the end of the day during which the patient takes 750 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    by mouth every four hours for six doses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/7\">",
"     7",
"    </a>",
"    ]. Urinary 17-OHCS excretion and serum 11-deoxycortisol are measured.",
"   </p>",
"   <p>",
"    A normal response to the two-day test has not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/7\">",
"     7",
"    </a>",
"    ]. In the differential diagnosis of ACTH-dependent Cushing's syndrome, however, a clear rise in plasma ACTH concentration indicates that the ACTH-secreting tumor responds to falling serum cortisol concentrations. In one large study, as an example, a positive response was defined as more than a 70 percent increase in urinary 17-OHCS excretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more than a fourfold increase in serum 11-deoxycortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Response in ACTH-dependent Cushing's syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overnight single-dose metyrapone test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single-dose test is performed by oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight, or 2 grams for &lt;70 kg, 2.5 grams for 70 to 90 kg, and 3 grams for &gt;90 kg body weight) at midnight with a glass of milk or a small snack [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/6\">",
"     6",
"    </a>",
"    ]. Serum 11-deoxycortisol and cortisol are measured between 7:30 and 9:30 AM the next morning; plasma ACTH can also be measured [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1,8-15\">",
"     1,8-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal response to the overnight single-dose test consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An 8 AM serum 11-deoxycortisol concentration of 7 to 22",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (200 to 660",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1,3,5,6,8\">",
"       1,3,5,6,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A serum cortisol concentration at 8 AM of less than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      confirms adequate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      blockade and thereby documents compliance and normal metabolism of metyrapone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum 11-deoxycortisol concentrations less than 7",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (210",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    with concomitantly suppressed cortisol values indicate adrenal insufficiency. However, in one study, the sum of 11-deoxycortisol and of cortisol &gt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (450",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    following single dose overnight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    yielded better diagnostic accuracy than using 11-deoxycortisol levels alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/2\">",
"     2",
"    </a>",
"    ]. In a study of 31 patients with various HPA axis abnormalities, comparing ITT with overnight metyrapone test, a cut-off of 144",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    for 11-deoxycortisol yielded the highest sensitivity of 82.4 percent to detect patients responding normally to ITT, but only 64.3 percent of those with sub-normal response to ITT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACTH response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    can distinguish between primary and secondary insufficiency. In general, patients with partial secondary adrenal insufficiency have ACTH responses from 10 to 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (2 to 44",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    while patients with primary adrenal insufficiency have higher responses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]. However, healthy individuals have an ACTH response of 42 to 690",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (9 to 210",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/13\">",
"     13",
"    </a>",
"    ]. Because of this overlap, the ACTH response alone cannot be used to distinguish between healthy individuals and those with adrenal insufficiency.",
"   </p>",
"   <p>",
"    The overnight single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test is probably as accurate as the two- or standard three-day tests. Its possible disadvantage is that it relies upon serum steroid concentrations at a single time rather than integrating excretion over 24 hours, but it is easier to conduct with fewer side effects.",
"   </p>",
"   <p>",
"    The single-dose test appears to be safe for outpatient use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1-3,8,17,18\">",
"     1-3,8,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By reducing cortisol production,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    can result in hypotension, nausea, vomiting, abdominal discomfort or cramping and muscle and joint pain in patients with adrenal insufficiency. Metyrapone can also cause dizziness, sedation, allergic rash or rarely decreased white blood cell count or bone marrow suppression.",
"   </p>",
"   <p>",
"    The two- and three-day tests should not be performed outside of the hospital in patients suspected of having adrenal insufficiency or primary adrenal Cushing's syndrome. If symptoms of adrenal insufficiency do occur, the patient should be given physiological saline solution and the test should be continued. Saline can usually be stopped a few hours after the last dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test is a very sensitive test of pituitary ACTH secretory reserve found to be more sensitive than insulin-tolerance test in certain studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/3\">",
"     3",
"    </a>",
"    ] or slightly less in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/16\">",
"     16",
"    </a>",
"    ]. It depends upon the release of pituitary ACTH secretion from negative feedback inhibition by cortisol; hypocortisolemia is a much less powerful stimulus to ACTH release than hypoglycemia or other stresses. Thus, a patient with partial hypopituitarism may maintain normal daily ACTH and cortisol secretion and respond to insulin-induced hypoglycemia with a normal increase in ACTH and cortisol secretion, yet be unable to increase ACTH secretion normally when cortisol biosynthesis is blocked by metyrapone (",
"    <a class=\"graphic graphic_figure graphicRef69011 \" href=\"UTD.htm?13/10/13486\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/8\">",
"     8",
"    </a>",
"    ]. Conversely, a patient who responds normally to metyrapone almost always responds normally to hypoglycemia or other stresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis of adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used to diagnose hypoadrenalism, a normal response to any of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    tests indicates an intact hypothalamic-pituitary-adrenal axis; such a patient does not have any form of adrenal insufficiency and requires no further investigation. An abnormal test could reflect either primary or secondary adrenal insufficiency. Distinction between the two can be determined by finding a high basal or stimulated plasma ACTH concentration, which would indicate primary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test is the most sensitive method to detect partial defects in pituitary ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thus, morning basal plasma ACTH and serum cortisol concentrations, basal urinary excretion of cortisol and 17-OHCS, and the responses to insulin-induced hypoglycemia and both the 1 and 250 mcg ACTH stimulation tests may all be normal, but the metyrapone test may be subnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. An example would be a patient with a suspected pituitary mass who has no clinical manifestations of ACTH deficiency, an intermediate 8 AM serum cortisol concentration, but an abnormal metyrapone test. If the metyrapone test is abnormal, the ability of the adrenal gland to respond to exogenous ACTH must always be demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rise in serum 11-deoxycortisol concentrations may be exaggerated in women taking an oral contraceptive and patients with hypothyroidism, hypoglycemia, diabetes mellitus, congestive heart failure, obesity, and chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     False positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are, however, settings in which false positive results can be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or chronic ingestion of synthetic glucocorticoids can result in a subnormal response as a result of suppression of the corticotropes.",
"     </li>",
"     <li>",
"      Any of the drugs that interfere in the assay for 17-OHCS can interfere with interpretation of the standard three-day test results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"       \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One of the more common causes of a false positive result is unusually rapid clearance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      from the plasma, resulting in inadequate blockade of cortisol biosynthesis. This is manifested by a serum cortisol concentration greater than 7.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (210",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in the sample drawn at 8 AM in the overnight test, or by a serum cortisol concentration greater than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (140",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      four hours after the last dose of metyrapone, or by urinary cortisol excretion greater than 20 mcg (55 nmol) per 24 hours the day metyrapone was administered in the standard two-day test. Cortisol levels measured by conventional immunoassays can be falsely elevated by the interference of increased 11-deoxycortisol levels induced by metyrapone; the eventual wider availability of liquid chromatography tandem mass spectrometry (MS) steroid assays should facilitate better interpretation of the results [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rapid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    clearance occurs in about 4 percent of normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/10,19\">",
"     10,19",
"    </a>",
"    ]. Metyrapone is metabolized by hepatic cytochrome P-450 enzymes that are induced by many of the same drugs that increase steroid metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ). As a result, these drugs should be stopped well before the metyrapone test is performed.",
"   </p>",
"   <p>",
"    An alternative is to perform the three-day test with twice the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    (750 mg every two hours for 12 doses; presumably, 1.5 g every four hours for six doses would be equally effective). A normal response is said to be indicated by a serum 11-deoxycortisol concentration greater than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    two hours after the last dose or urinary 17-OHCS excretion of more than 6 mg (17 nmol) per 24 hours on the day of metyrapone administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, because the double dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    is given to overcome the increased metabolic clearance, it is not clear why the criterion for a normal response should be different from that in the standard three-day test. Consequently, one can reasonably assume that a two- to threefold increase above the baseline 24-hour 17-OHCS excretion during the day of or the day after metyrapone administration is indicative of normal ACTH secretory reserve. Furthermore, if baseline urinary 17-OHCS excretion is 6 mg (17 nmol) or more per 24 hours, a similar value on the day of metyrapone indicates a lack of response. Such a lack of response, despite normal or high basal urinary 17-OHCS excretion, might occur in a patient with a cortisol-secreting adrenal tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Response in ACTH-dependent Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with proven ACTH-dependent Cushing's syndrome, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test can be used to help distinguish between a pituitary tumor (Cushing's disease) and ectopic ACTH secretion as the cause of the Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a report of 196 patients with ACTH-dependent Cushing's syndrome, 15 of whom had surgically confirmed ectopic ACTH secretion, a positive response, suggestive of Cushing's disease, consisted of at least a 70 percent increase in urinary 17-OHCS excretion and a fourfold increase in serum 11-deoxycortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/7\">",
"     7",
"    </a>",
"    ]. None of the patients with ectopic ACTH secretion fulfilled either of these criteria. On the other hand, when both criteria were exceeded, the sensitivity for the diagnosis of Cushing's disease was 71 percent. The sensitivity could be increased to 88 percent in patients who satisfied criteria for both the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test.",
"   </p>",
"   <p>",
"    The rate of steroid production after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    may be very high in patients with Cushing's disease because it starts from a much higher baseline than normal. The reason for the increase after metyrapone is that the microadenoma responds to hypocortisolemia with a greater than normal increase in ACTH secretion and the hyperplastic adrenal cortex is able to respond with still greater steroid production.",
"   </p>",
"   <p>",
"    In general, the response in the patients with the ectopic ACTH syndrome depends upon the duration and severity of hypercortisolism. Patients with long-standing ectopic ACTH secretion do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    (or to increased serum glucocorticoid concentrations resulting from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test), presumably because their hypothalamic-pituitary axis is chronically and profoundly suppressed.",
"   </p>",
"   <p>",
"    The response may be different when the hypercortisolemia is of relatively short duration, because hypothalamic-pituitary suppression may be incomplete. Thus, although the tumors do not respond to hypocortisolemia with increased ACTH secretion, the normal pituitary is able to secrete some ACTH, and the hyperplastic adrenals are able to respond to even a small increment in plasma ACTH with increased cortisol secretion. These patients tend to have a less than normal response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , but their urinary 17-OHCS secretion rarely falls. However, some patients with bronchial carcinoid tumors may respond to metyrapone in the setting of chronic hypercortisolism, suggesting that hypocortisolism can modulate tumoral secretion of ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Response in cortisol-producing adrenal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with adrenal tumors and, presumably, other forms of primary adrenal hypersecretion, almost always have a",
"    <strong>",
"     fall",
"    </strong>",
"    in urinary 17-OHCS excretion when given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16135/abstract/24\">",
"     24",
"    </a>",
"    ]. The decrease occurs for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chronic hypercortisolemia has suppressed hypothalamic CRH and pituitary ACTH synthesis and secretion. As a result, little ACTH is released in response to the hypocortisolemia induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Adrenal carcinomas and about half of adenomas do not respond even to exogenous stimulation with pharmacological levels of ACTH.",
"     </li>",
"     <li>",
"      The normal adrenal cortex is atrophic because of prolonged ACTH deficiency and is unable to respond acutely.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       Metyrapone",
"      </a>",
"      also blocks earlier steps in cortisol biosynthesis, leading to a reduction in total 17-OHCS excretion. The latter consists of tetrahydrocortisol (THF), tetrahydrocortisone (THE), both of which fall, and tetrahydro-11-deoxycortisol (THS), which increases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      stimulation test is based upon the principle that decreasing serum cortisol concentrations is expected to produce an increase in corticotropin (ACTH) secretion. It is the most sensitive test to detect partial defects in pituitary ACTH secretion.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       Metyrapone",
"      </a>",
"      blocks the conversion of 11-deoxycortisol to cortisol by CYP11B1 (11-beta-hydroxylase, P-450c11), the last step in the synthesis of cortisol, and induces a rapid fall of cortisol (",
"      <a class=\"graphic graphic_figure graphicRef56413 \" href=\"UTD.htm?42/12/43212\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In healthy individuals, the fall in serum cortisol concentrations leads sequentially to increases in ACTH secretion, adrenal steroidogenesis, and the secretion of cortisol precursors, in particular, 11-deoxycortisol, which can be measured by radioimmunoassay, HPLC, or in urine as a 17-hydroxycorticosteroid (17-OHCS) (",
"      <a class=\"graphic graphic_figure graphicRef81918 \" href=\"UTD.htm?9/7/9342\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In addition to the detection of ACTH deficiency, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      stimulation test can also be used in the evaluation of patients with ACTH-dependent Cushing's syndrome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Response in ACTH-dependent Cushing's syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test can be performed as an overnight single-dose test or as a two- or three-day test (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Procedure'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The three-day test is used mainly for the evaluation of adrenal insufficiency.",
"     </li>",
"     <li>",
"      The two-day test is used primarily in the differential diagnosis of hypercortisolism.",
"     </li>",
"     <li>",
"      The single-dose overnight test can be used for both indications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    administration may result in hypotension, nausea, and vomiting in patients with adrenal insufficiency; as a result, the two- and three-day tests should not be performed outside of the hospital in patients suspected of having this disorder. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Drug side effects'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/1\">",
"      Fiad TM, Kirby JM, Cunningham SK, McKenna TJ. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1994; 40:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/2\">",
"      Berneis K, Staub JJ, Gessler A, et al. Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab 2002; 87:5470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/3\">",
"      Gibney J, Healy ML, Smith TP, McKenna TJ. A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores. J Clin Endocrinol Metab 2008; 93:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/4\">",
"      LIDDLE GW, ESTEP HL, KENDALL JW Jr, et al. Clinical application of a new test of pituitary reserve. J Clin Endocrinol Metab 1959; 19:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/5\">",
"      Jubiz W, Matsukura S, Meikle AW, et al. Plasma metyrapone, adrenocorticotropic hormone, cortisol, and deoxycortisol levels. Sequential changes during oral and intravenous metyrapone administration. Arch Intern Med 1970; 125:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/6\">",
"      Jubiz W, Meikle AW, West CD, Tyler FH. Single-dose metyrapone test. Arch Intern Med 1970; 125:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/7\">",
"      Avgerinos PC, Yanovski JA, Oldfield EH, et al. The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 1994; 121:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/8\">",
"      Steiner H, B&auml;hr V, Exner P, Oelkers PW. Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp Clin Endocrinol 1994; 102:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/9\">",
"      Staub JJ, Noelpp B, Girard J, et al. The short metyrapone test: comparison of the plasma ACTH response to metyrapone and insulin-induced hypoglycaemia. Clin Endocrinol (Oxf) 1979; 10:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/10\">",
"      Feek CM, Bevan JS, Ratcliffe JG, et al. The short metyrapone test: comparison of the plasma ACTH response to metyrapone with the cortisol response to insulin-induced hypoglycaemia in patients with pituitary disease. Clin Endocrinol (Oxf) 1981; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/11\">",
"      Dolman LI, Nolan G, Jubiz W. Metyrapone test with adrenocorticotrophic levels. Separating primary from secondary adrenal insufficiency. JAMA 1979; 241:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/12\">",
"      Mahajan DK, Wahlen JD, Tyler FH, West CD. Plasma 11-deoxycortisol radioimmunoassay for metyrapone tests. Steroids 1972; 20:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/13\">",
"      Endert E, Ouwehand A, Fliers E, et al. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med 2005; 63:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/14\">",
"      Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf) 2002; 56:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/15\">",
"      Z&ouml;llner EW, Lombard C, Galal U, et al. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids--more common than expected? J Pediatr Endocrinol Metab 2011; 24:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/16\">",
"      Giordano R, Picu A, Bonelli L, et al. Hypothalamus-pituitary-adrenal axis evaluation in patients with hypothalamo-pituitary disorders: comparison of different provocative tests. Clin Endocrinol (Oxf) 2008; 68:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/17\">",
"      Dickstein G, Lahav M, Orr ZS. Single-dose metyrapone test at 06.00 h: an accurate method for assessment of pituitary-adrenal reserve. Acta Endocrinol (Copenh) 1986; 112:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/18\">",
"      Soule S, Van Zyl Smit C, Parolis G, et al. The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism. Clin Endocrinol (Oxf) 2000; 53:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/19\">",
"      Spiger M, Jubiz W, Meikle AW, et al. Single-dose metyrapone test: review of a four-year experience. Arch Intern Med 1975; 135:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/20\">",
"      Nolan GE, Smith JB, Chavre VJ, Jubiz W. Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab 1981; 52:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/21\">",
"      Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem 2010; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/22\">",
"      Meikle AW, Jubiz W, Matsukura S, et al. Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man. J Clin Endocrinol Metab 1969; 29:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/23\">",
"      Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16135/abstract/24\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 162 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16135=[""].join("\n");
var outline_f15_48_16135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Standard three-day metyrapone test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Two-day metyrapone test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overnight single-dose metyrapone test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis of adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - False positives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Response in ACTH-dependent Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Response in cortisol-producing adrenal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/162|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43212\" title=\"figure 1\">",
"      Action of metyrapone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/7/9342\" title=\"figure 2\">",
"      Normal response to metyrapone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/10/13486\" title=\"figure 3\">",
"      Metyrapone in hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=related_link\">",
"      Insulin-induced hypoglycemia test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16136="Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)";
var content_f15_48_16136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16136/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16136/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16136/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/48/16136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every four to ten residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation (disorders of glycogenosis or glycogenoses). Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen is the primary source of energy for high intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review glucose-6-phosphatase deficiency (GSD I, MIM #232200), also known as von Gierke disease. An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of GSD I is",
"    <span class=\"nowrap\">",
"     1/100,000",
"    </span>",
"    live births [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/1\">",
"     1",
"    </a>",
"    ]. It is one of the most common types of glycogen storage diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hydrolysis and transport of glucose 6-phosphate requires a catalytic hydrolase and microsomal transporters for glucose 6-phosphate, pyrophosphate, and glucose (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    GSD Ia is due to a deficiency in the glucose 6-phosphate hydrolase activity and comprises over 80 percent of cases. GSD Ib (glucose-6-phosphate transporter deficiency), Ic, and Id are allelic defects in the glucose 6-phosphate translocase that is functionally associated with glucose-6-phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/2\">",
"     2",
"    </a>",
"    ]. The translocase functions as both a G6P transporter and a phosphate antiporter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expression of glucose-6-phosphatase appears to be modulated by steroid receptor coactivator 2 (SRC-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/4\">",
"     4",
"    </a>",
"    ]. Ablation of SRC-2 in a mouse-model resulted in a phenotype similar to that of glucose-6-phosphatase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSD I is an autosomal recessive disorder. The genes responsible for GSD I have been isolated and mutations described in both type Ia and Ib patients. The glucose 6-phosphatase gene (G6PC) that encodes the hydrolase is located at 17q21. The gene encoding glucose 6-phosphate translocase (G6PT) is at 11q23.",
"   </p>",
"   <p>",
"    Almost 100 mutations have been identified in the G6PC gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Most are",
"    <span class=\"nowrap\">",
"     missense/nonsense",
"    </span>",
"    mutations, although other types of deletions have been reported. A limited number of mutations account for the majority of GSD Ia patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      R83C and Q347X are the most prevalent mutations found in Caucasians [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      130X (a 2 nucleotide insertion) and R83C are most prevalent in Hispanics [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      R83H is most prevalent in Chinese [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A splice site mutation, 727G-T, accounts for most mutant alleles in Japan (88 of 102 mutant alleles) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      R83C is the most prevalent, and possibly the exclusive, mutation in the Ashkenazi Jewish population [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GSD Ib mutations appear more heterogeneous, although in 22 families studied G339C and 1211-1212delCT accounted for approximately 40 percent of the disease alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients typically present in early infancy with hepatomegaly, hypoglycemia (with related signs, such as seizures), and lactic acidosis. In a report from the collaborative European Study on Glycogen Storage Disease type I, patients with GSD Ia and GSD Ib presented at a median age of six months (range 1 day to 12 years) and four months (range one day to four years), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/11\">",
"     11",
"    </a>",
"    ]. The majority of both types presented before one year of age in this series. However, a subsequent case report described a man who was a long distance runner and required no carbohydrate supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/12\">",
"     12",
"    </a>",
"    ]. He was diagnosed at 42 years of age after presenting with hepatocellular carcinoma.",
"   </p>",
"   <p>",
"    In the European study, the following were the dominant presenting features [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protruding abdomen &mdash; 83 percent",
"     </li>",
"     <li>",
"      Metabolic derangement &mdash; 71 percent",
"     </li>",
"     <li>",
"      Growth failure &mdash; 25 percent",
"     </li>",
"     <li>",
"      Recurrent infections &mdash; 3 percent in GSD Ia, 41 percent in GSD Ib",
"     </li>",
"     <li>",
"      Muscular hypotonia &mdash; 13 percent",
"     </li>",
"     <li>",
"      Delayed psychomotor development &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet dysfunction is common, with frequent epistaxis. Patients with GSD Ib also have chronic or intermittent neutropenia and neutrophil dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/1\">",
"     1",
"    </a>",
"    ]. In a report from a European registry of 57 GSD Ib patients, neutropenia occurred in 54 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/13\">",
"     13",
"    </a>",
"    ]. It was documented before one year of age in 64 percent of patients, but was first noted between six and nine years in 18 percent. Neutropenia was intermittent without a clear cyclical course in 45 patients, and persistent in five. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioral and perianal infections, abscesses, and inflammatory bowel disease are common. Rare type Ib patients avoid the latter complication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short stature is common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/15\">",
"     15",
"    </a>",
"    ]. Puberty often is delayed and polycystic ovaries are observed, although successful pregnancies have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease results from glycogen accumulation in the kidney. Proteinuria, hematuria, nephrocalcinosis, and altered creatinine clearance typically follow a period of asymptomatic hyperfiltration. The kidney appears enlarged, and histologic examination reveals focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension is common, with a subset of patients developing progressive renal insufficiency (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GSD I have altered brain function and structure. In one study comparing brain function and morphology between patients with GSD I and age- and sex-matched controls, subjects with GSD I had increased prevalence of abnormal electroencephalograms (26 versus 3 percent); visual evoked potentials (38 versus 8 percent); somatosensory evoked potentials (23 versus 0 percent); brainstem auditory evoked potentials (16 versus 0 percent); and magnetic resonance imaging (MRI) studies (57 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/21\">",
"     21",
"    </a>",
"    ]. MRI abnormalities included dilation of the occipital horns",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperintensity of subcortical white matter in the occipital or parietal lobes. While some of these abnormalities correlated with the frequency of hypoglycemic episodes requiring hospitalization, the contribution of other factors, directly or indirectly related to GSD I, remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have hyperuricemia and marked hyperlipidemia, especially hypertriglyceridemia, which can lead to xanthoma formation and pancreatitis. De novo triglyceride synthesis has been shown to increase over 10-fold in affected individuals, and the conversion of VLDL to LDL is retarded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/22\">",
"     22",
"    </a>",
"    ]. The relationship between hyperlipidemia and cardiovascular disease in patients with GSD I is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/23\">",
"     23",
"    </a>",
"    ]. The finding of increased carotid intima media thickening suggests that the risk of vascular dysfunction may be increased, but case series have yielded inconsistent observations regarding vascular dysfunction and markers of cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older children and adults often develop liver adenomas that undergo malignant transformation in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications due to GSD I persist in adults. In one report, long-term outcome was evaluated in 37 patients with type Ia GSD and five patients with type Ib GSD who were &ge;18 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/27\">",
"     27",
"    </a>",
"    ]. The following outcomes were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatomegaly &mdash; 100 percent",
"     </li>",
"     <li>",
"      Short stature &mdash; 90 percent",
"     </li>",
"     <li>",
"      Hyperuricemia &mdash; 89 percent",
"     </li>",
"     <li>",
"      Anemia &mdash; 81 percent",
"     </li>",
"     <li>",
"      Hypercholesterolemia &mdash; 76 percent",
"     </li>",
"     <li>",
"      Increased serum triglycerides &mdash; 100 percent",
"     </li>",
"     <li>",
"      Hepatic adenomas &mdash; 75 percent",
"     </li>",
"     <li>",
"      Proteinuria or microalbuminuria &mdash; 67 percent",
"     </li>",
"     <li>",
"      Renal calcifications &mdash;65 percent",
"     </li>",
"     <li>",
"      Osteopenia or fractures &mdash; 27 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients develop pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSD I should be suspected in patients with lactic acidemia, hypoglycemia, hyperlipidemia, and hepatomegaly, with or without neutropenia. Serum biotinidase is significantly elevated in GSD I and other glycogen storage disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first step in confirming the diagnosis is DNA testing for common mutations. If none is identified, liver biopsy should be performed.",
"   </p>",
"   <p>",
"    Liver histology demonstrates prominent storage of glycogen and considerable steatosis with minimal fibrosis. Enzyme analysis of fresh and frozen samples can distinguish GSD Ia from Ib. Since freezing disrupts lipid membranes, glucose 6-phosphate translocase deficiency can be demonstrated in fresh, but not frozen tissue, while glucose 6-phosphatase deficiency (as in GSD Ia) is observed in both fresh and frozen tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is the maintenance of physiologic glucose levels. Other biochemical parameters, such as lactic acidemia and hypertriglyceridemia, improve in parallel with improved glucose control.",
"   </p>",
"   <p>",
"    Guidelines for the management of GSD I were published by the Collaborative European Study on Glycogen Storage Disease I [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"     31",
"    </a>",
"    ]. The following recommendations were made for appropriate biomedical targets:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preprandial blood glucose &gt;3.5 to 4.0",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (63 to 72",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Urine",
"      <span class=\"nowrap\">",
"       lactate/creatinine",
"      </span>",
"      ratio &lt;0.06",
"      <span class=\"nowrap\">",
"       mmol/mmol",
"      </span>",
"     </li>",
"     <li>",
"      Serum uric acid concentration in high normal range for age",
"     </li>",
"     <li>",
"      Venous blood base excess &gt;-5",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      and venous blood bicarbonate &gt;20",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum triglyceride concentration &lt;6.0",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (531",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Normal fecal alpha-1 antitrypsin concentration for GSD Ib",
"     </li>",
"     <li>",
"      Body mass index between 0.0 and + 2.0 SDs (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"       calculator 3",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"       calculator 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrates other than cornstarch (a glucose polymer), such as lactose, galactose, fructose, and sucrose, should be minimized in the diet since they also depend upon glucose 6-phosphatase activity for metabolism.",
"   </p>",
"   <p>",
"    A high protein diet is not useful to maintain glucose, since gluconeogenesis also depends upon hydrolysis of glucose 6-phosphate.",
"   </p>",
"   <p>",
"    Essential vitamins and minerals, especially calcium, should be provided through the diet or by supplementation, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15153517\">",
"    <span class=\"h3\">",
"     Uncooked cornstarch and maltodextrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose concentrations are maintained with frequent administration of uncooked cornstarch (UCS). The dose is 1.5 to 2.5",
"    <span class=\"nowrap\">",
"     gm/kg,",
"    </span>",
"    given orally every four to six hours (one Tablespoon equals approximately 8.6 grams). Since infants may not digest cornstarch well, they can be breastfed or given formula that is lactose-free with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38865?source=see_link\">",
"     maltodextrin",
"    </a>",
"    added [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"     31",
"    </a>",
"    ]. After six months, the maltodextrin can be replaced by rice or corn.",
"   </p>",
"   <p>",
"    After one year of age, children should be given at least three daily meals with uncooked cornstarch and frequent snacks in between. During the night, continuous gastrostomy feeding is optimal, although cornstarch feeding before bedtime can maintain glucose concentration in many patients.",
"   </p>",
"   <p>",
"    In a pilot study, the use of physically modified cornstarch (waxy maize heat modified 20, WMHM20), a form of starch containing higher amounts of branched polymers, provided better short-term metabolic control and longer duration of euglycemia than uncooked cornstarch in patients with GSD Ia, Ib, and III [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/32\">",
"     32",
"    </a>",
"    ]. Additional studies are needed before this therapy can be recommended.",
"   </p>",
"   <p>",
"    Long-term treatment with UCS improves growth in GSD I patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. One report evaluated the effect of UCS in 26 patients with GSD Ia who were treated with UCS for an average of 14.1 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/34\">",
"     34",
"    </a>",
"    ]. When they were evaluated at an average age of 20.8 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Height (measured by a mean standard deviation score) was significantly lower than the target height; weight and body mass were not affected. Improved height correlated with a higher serum bicarbonate and greater body mass, reflecting better metabolic control.",
"     </li>",
"     <li>",
"      At least one focal hepatic lesion consistent with adenoma was found in 50 percent.",
"     </li>",
"     <li>",
"      Urinary albumin excretion was increased in 31 percent and two patients had clinically significant albuminuria.",
"     </li>",
"     <li>",
"      Anemia occurred in 50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications were more frequent in patients who had suboptimal metabolic control. Patients without complications had blood lactate and bicarbonate concentrations that were close to normal.",
"   </p>",
"   <p>",
"    In another study, outcomes were compared in six patients with GSD I treated with UCS and seven who received continuous nocturnal nasogastric tube feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/35\">",
"     35",
"    </a>",
"    ]. After at least five years of treatment, the groups were similar in linear growth rate and height, and blood concentrations of glucose, lactate, cholesterol, and triglyceride. Adverse effects of UCS were limited to diarrhea, increased flatulence, and excess weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15153529\">",
"    <span class=\"h3\">",
"     Diazoxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"     Diazoxide",
"    </a>",
"    has been shown to improve glucose control, probably by inhibiting glucose-induced insulin release, although this is",
"    <strong>",
"     not",
"    </strong>",
"    routinely used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    should be started if the serum uric acid concentration exceeds the upper range of normal for age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"     31",
"    </a>",
"    ]. Use of medium chain triglyceride oil was shown in two small studies to improve uric acid levels and reduce carbohydrate requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactic acidosis should be corrected with bicarbonate in a starting dose of 1 to 2 mmol (85 to 170 mg) per kg per day orally in four doses. Bicarbonate administration also alkalinizes the urine, which decreases the risk of urolithiasis and nephrocalcinosis. Alkalinization with potassium citrate (5 to 10 meq every 12 hours orally) may be a better approach, because hypocitraturia appears to worsen with age in GSD Ia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An angiotensin converting enzyme (ACE) inhibitor should be started in patients with persistent microalbuminuria to decrease deterioration of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"     31",
"    </a>",
"    ]. Hypertension that persists despite ACE inhibition should also be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The persistently elevated serum cholesterol concentration in GSD Ia is not associated with premature atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, drugs that lower cholesterol are",
"    <strong>",
"     not",
"    </strong>",
"    recommended in children. Dietary interventions (eg, administration of medium-chain triglyceride milk) may be effective at reducing triglyceride and lactic acid levels by improving fatty acid oxidation and reducing glycolysis, but require additional evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies without clear benefit are fish oil and growth hormone. Fish oil does not persistently lower serum triglyceride and cholesterol concentration and may increase atherogenesis by increasing lipoprotein oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of inflammatory bowel disease with 5-aminosalicylic acid, antibiotics, G-CSF, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone does not affect the final height [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSD Ib patients with neutropenia should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (GCSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In a report from the European registry, GCSF increased the neutrophil count, decreased the frequency and severity of infections, and subjectively improved the severity of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/44\">",
"     44",
"    </a>",
"    ]. Splenomegaly was the most serious complication of GCSF, and occurred in 4 of 18 patients treated.",
"   </p>",
"   <p>",
"    Reactive oxygen species are thought to play a role in activating apoptosis in neutrophils of patients with GSD Ib, suggesting that antioxidant therapy may be beneficial. This hypothesis was evaluated in an observational study in which seven patients with GSD Ib were treated with vitamin E for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/45\">",
"     45",
"    </a>",
"    ]. Vitamin E supplementation was associated with increased mean neutrophil counts and decreased frequency and severity of infections, mouth ulcers, and perianal lesions compared with the year before supplementation. The improvements disappeared after cessation of treatment. These findings show promise as an adjunct or alternative treatment, but should be replicated in larger, placebo-controlled trials before vitamin E therapy can be routinely suggested for the treatment of patients with GSD Ib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation has been performed in some affected patients with poor metabolic control, hepatocellular carcinoma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver failure. The procedure greatly improves metabolic control [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, growth does not usually improve and neutropenia persists in type Ib. The effect on renal disease is uncertain. Hepatocyte transplantation may be a future alternative to liver transplantation, but further studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/48\">",
"     48",
"    </a>",
"    ]. Complete resolution of hypoglycemia, eliminating the need for UCS, has been reported in one individual with GSD Ib [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16136/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose-6-phosphatase deficiency (GSD I), also known as von Gierke disease, is an autosomal recessive disorder caused by a deficiency of glucose 6-phosphate hydrolase activity (type Ia) or defects in the glucose 6-phosphate translocase that is functionally associated with glucose-6-phosphatase (types Ib, Ic, and Id) (",
"      <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Affected patients typically present in early infancy with hepatomegaly, hypoglycemia, seizures,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lactic acidosis. Additional manifestations include growth failure, recurrent infections, hypotonia, delayed development, renal disease, and hyperuricemia, and hyperlipidemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in confirming the diagnosis is DNA testing for common mutations or full gene sequencing. If no mutations are identified, liver biopsy should be performed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment is the maintenance of physiologic glucose levels. Other biochemical parameters, such as lactic acidemia and hypertriglyceridemia, improve in parallel with improved glucose control. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucose concentrations are maintained with frequent administration of uncooked cornstarch. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional treatment measures may be necessary for hyperuricemia, lactic acidosis, hyperlipidemia, microalbuminuria, hypertension, and neutropenia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/1\">",
"      Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr 2005; 164:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/2\">",
"      Gerin I, Veiga-da-Cunha M, Achouri Y, et al. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. FEBS Lett 1997; 419:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/3\">",
"      Chen SY, Pan CJ, Nandigama K, et al. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J 2008; 22:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/4\">",
"      Chopra AR, Louet JF, Saha P, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 2008; 322:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/5\">",
"      Chou JY, Mansfield BC. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 2008; 29:921.",
"     </a>",
"    </li>",
"    <li>",
"     The Human Gene Mutation Database at file://www.hgmd.cf.ac.uk/ac/index.php (Accessed on October 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/7\">",
"      Lei KJ, Chen YT, Chen H, et al. Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 1995; 57:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/8\">",
"      Akanuma J, Nishigaki T, Fujii K, et al. Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells. Am J Med Genet 2000; 91:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/9\">",
"      Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/10\">",
"      Veiga-da-Cunha M, Gerin I, Chen YT, et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. Am J Hum Genet 1998; 63:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/11\">",
"      Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/12\">",
"      Cassiman D, Libbrecht L, Verslype C, et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia. J Hepatol 2010; 53:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/13\">",
"      Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/14\">",
"      Roe TF, Thomas DW, Gilsanz V, et al. Inflammatory bowel disease in glycogen storage disease type Ib. J Pediatr 1986; 109:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/15\">",
"      Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002; 161 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/16\">",
"      Ryan IP, Havel RJ, Laros RK Jr. Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease). Am J Obstet Gynecol 1994; 170:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/17\">",
"      Sechi A, Deroma L, Lapolla A, et al. Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. J Inherit Metab Dis 2013; 36:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/18\">",
"      Chen YT, Coleman RA, Scheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med 1988; 318:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/19\">",
"      Chen YT. Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol 1991; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/20\">",
"      Reitsma-Bierens WC. Renal complications in glycogen storage disease type I. Eur J Pediatr 1993; 152 Suppl 1:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/21\">",
"      Melis D, Parenti G, Della Casa R, et al. Brain damage in glycogen storage disease type I. J Pediatr 2004; 144:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/22\">",
"      Bandsma RH, Prinsen BH, van Der Velden Mde S, et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 2008; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/23\">",
"      Bernier AV, Correia CE, Haller MJ, et al. Vascular dysfunction in glycogen storage disease type I. J Pediatr 2009; 154:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/24\">",
"      Ubels FL, Rake JP, Slaets JP, et al. Is glycogen storage disease 1a associated with atherosclerosis? Eur J Pediatr 2002; 161 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/25\">",
"      Lee PJ, Celermajer DS, Robinson J, et al. Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis 1994; 110:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/26\">",
"      Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/27\">",
"      Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994; 120:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/28\">",
"      Furukawa N, Kinugasa A, Inoue F, et al. Type I glycogen storage disease with vasoconstrictive pulmonary hypertension. J Inherit Metab Dis 1990; 13:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/29\">",
"      Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/30\">",
"      Paesold-Burda P, Baumgartner MR, Santer R, et al. Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarker. J Inherit Metab Dis 2007; 30:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/31\">",
"      Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/32\">",
"      Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 2007; 30:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/33\">",
"      Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 1984; 310:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/34\">",
"      Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/35\">",
"      Chen YT, Bazzarre CH, Lee MM, et al. Type I glycogen storage disease: nine years of management with cornstarch. Eur J Pediatr 1993; 152 Suppl 1:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/36\">",
"      Nuoffer JM, Mullis PE, Wiesmann UN. Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth. J Inherit Metab Dis 1997; 20:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/37\">",
"      Nagasaka H, Hirano K, Ohtake A, et al. Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur J Pediatr 2007; 166:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/38\">",
"      Das AM, L&uuml;cke T, Meyer U, et al. Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Ann Nutr Metab 2010; 56:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/39\">",
"      Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/40\">",
"      Bandsma RH, Rake JP, Visser G, et al. Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. J Pediatr 2002; 140:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/41\">",
"      Davis MK, Rufo PA, Polyak SF, Weinstein DA. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/42\">",
"      Schroten H, Roesler J, Breidenbach T, et al. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib. J Pediatr 1991; 119:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/43\">",
"      Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002; 161 Suppl 1:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/44\">",
"      Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161 Suppl 1:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/45\">",
"      Melis D, Della Casa R, Parini R, et al. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b. Eur J Pediatr 2009; 168:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/46\">",
"      Faivre L, Houssin D, Valayer J, et al. Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia. J Inherit Metab Dis 1999; 22:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/47\">",
"      Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999; 158 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/48\">",
"      Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16136/abstract/49\">",
"      Lee KW, Lee JH, Shin SW, et al. Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant 2007; 16:629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2946 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16136=[""].join("\n");
var outline_f15_48_16136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15153517\">",
"      - Uncooked cornstarch and maltodextrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15153529\">",
"      - Diazoxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Short stature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2946|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 3\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 4\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16137="PJS duodenal polyp Light";
var content_f15_48_16137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1107px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal Peutz-Jeghers polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a duodenal Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal small intestinal epithelium; the overlying epithelium is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Normal small intestine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 168px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of the normal villous architecture of the small intestine. The high power view shows the enterocytes and interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16137=[""].join("\n");
var outline_f15_48_16137=null;
var title_f15_48_16138="Familial amyotrophic lateral sclerosis";
var content_f15_48_16138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Familial amyotrophic lateral sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Leo McCluskey, MD, MBE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Dana Falcone, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/48/16138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/48/16138/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/48/16138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is one specific type of the more general group of motor neuron diseases. These disorders variably affect motor neurons located in the anterior (ventral) horn regions of the spinal cord, the cranial nerve motor nuclei in the pons and medulla, and the frontal cortex. Familial amyotrophic lateral sclerosis accounts for 5 to 10 percent of all ALS cases.",
"   </p>",
"   <p>",
"    ALS is a relentlessly progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death. The hallmark of ALS is the combination of upper motor neuron (UMN) and lower motor neuron (LMN) involvement. The LMN findings of weakness, atrophy, and fasciculations are a direct consequence of muscle denervation, hence the term \"amyotrophic.\" The UMN findings of hyperreflexia and spasticity result from degeneration of the lateral corticospinal tracts in the spinal cord, which are gliotic and hardened to palpation at autopsy, hence the term \"lateral sclerosis.\"",
"   </p>",
"   <p>",
"    This topic review will discuss familial ALS. The epidemiology and clinical features of ALS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136713437\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS accounts for approximately 5 to 10 percent of all ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], with the rest being sporadic (idiopathic) in origin. In our series of 399 cases of ALS at the University of Pennsylvania with a four-generation pedigree, 10 percent of individuals had an affected first or second-degree relative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial ALS is phenotypically and genetically heterogeneous. Although most familial ALS cases follow an autosomal dominant inheritance pattern, recessive and X-linked forms have been described. At least 15 different loci are thought to harbor ALS-causing mutations. The nomenclature of ALS1 through ALS15 arises from the order of their discovery and not from any particular clinical classification. Many of the types listed have been described only in one or two families, and genotype-phenotype correlation is stronger for some forms of genetic ALS than for others. In most individual cases, it may be difficult to determine on clinical grounds alone if ALS is familial or sporadic, especially at the onset of disease. The presence of atypical features such as young age of onset, sensory loss, and of course a positive family history of ALS, other neurodegenerative disorders, and dementia should alert the clinician to the possibility of familial ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOSOMAL DOMINANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of familial ALS cases follow an autosomal dominant inheritance pattern. In autosomal dominant inheritance, having a mutation in only one copy of a gene is sufficient for an individual to develop the condition. Typically, the copy of the gene with the mutation is inherited from a parent (as opposed to de novo mutations, which are uncommon), and most individuals with an autosomal dominant condition will have a positive family history. The children of a parent with a dominant mutation have a 50 percent chance of inheriting the copy of the gene with the mutation and developing ALS.",
"   </p>",
"   <p>",
"    Autosomal dominant mutations in apparently sporadic ALS can occur due to de novo (new) mutations, reduced penetrance, or insufficient family history information. The frequency of de novo mutations in ALS is unknown. The recurrence risk for siblings and parents of an apparently sporadic ALS case with an autosomal dominant mutation depends on whether or not the affected individual has an inherited or a de novo mutation. If the individual with ALS inherited the mutation from a parent, there is a 50 percent chance the individual&rsquo;s siblings and children will inherit the mutation and be at risk to develop ALS. In the case of a de novo mutation, the recurrence risk for siblings would be low, but the recurrence risk for children would be 50 percent.",
"   </p>",
"   <p>",
"    The most common autosomal dominantly inherited forms of familial ALS are caused by mutations in the C9ORF72 gene (see",
"    <a class=\"local\" href=\"#H1808661\">",
"     'C9ORF72 gene'",
"    </a>",
"    below) and the SOD1 gene (see",
"    <a class=\"local\" href=\"#H3\">",
"     'ALS1 (SOD1 gene)'",
"    </a>",
"    below) described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1808661\">",
"    <span class=\"h2\">",
"     C9ORF72 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat expansions of the C9ORF72 gene on chromosome 9p21 are causally linked to classic ALS, frontotemporal dementia, and ALS with frontotemporal dementia. These expansions appear to be the most common cause of familial ALS, accounting for 24 to 47 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. In addition, C9ORF72 expansions are observed in 4 to 20 percent of sporadic ALS cases in these studies.",
"   </p>",
"   <p>",
"    Earlier reports described familial forms of ALS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frontotemporal dementia (FTD) linked to chromosome 9p with adult onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In these families, some individuals manifest both ALS and FTD, while others have FTD without ALS, or ALS without FTD. The dementia may precede, follow, or develop simultaneously with the onset of upper and lower motor neuron signs; it produces personality change, executive dysfunction, or language difficulties. Most of these cases of ALS and FTD linked to chromosome 9 are explained by a dominantly inherited form of familial ALS and FTD (FTDALS) caused by pathologic expansion of a noncoding GGGGCC hexanucleotide repeat in the C9ORF72 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The C9ORF72 gene encodes an uncharacterized protein that is highly conserved among species. The hexanucleotide repeat expansion seen in FTDALS cases is large, ranging from 250 to 1,600 repeats, compared with &lt;24 repeats in controls. In a population-based study from Ireland, the C9ORF72 expansion was found in 20 of 49 cases (41 percent) of FALS and 19 of 386 (5 percent) apparently sporadic cases of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/6\">",
"     6",
"    </a>",
"    ]. Among 191 cases with phenotype data, the repeat expansion was present in 21 (11 percent). Compared with those without the C9ORF72 repeat expansion, patients with the expansion had the following statistically significant findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Earlier disease onset (mean age 56.3 versus 61.3 years)",
"     </li>",
"     <li>",
"      Higher frequency of comorbid FTD (50 versus 12 percent)",
"     </li>",
"     <li>",
"      Shorter age-matched median survival (20 versus 26 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, the C9ORF72 repeat expansion was not found in patients with sporadic ALS who had normal cognition and no family history of neurodegenerative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another locus for families with FTD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ALS was previously identified on chromosome 9q [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/14\">",
"     14",
"    </a>",
"    ], but this finding has not been replicated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cognitive features of ALS and the manifestations of FTD are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Cognitive symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ALS1 (SOD1 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS1 represents about 12 to 20 percent of familial ALS cases and is linked to mutations of the copper-zinc (Cu,Zn) superoxide dismutase type 1 (SOD1) gene localized in chromosome 21q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Most are inherited in an autosomal dominant manner. Over 140 mutations of the SOD1 gene have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinical features of ALS1 are variable, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The A4V missense mutation is the most prevalent mutation in familial ALS1 and accounts for about 41 percent of patients with SOD1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/20\">",
"       20",
"      </a>",
"      ]. It typically has a rapid progression with an average life expectancy of 1.5 years after the onset of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/21\">",
"       21",
"      </a>",
"      ]. Upper motor neuron involvement is either absent or mild, but pathological abnormalities in systems other than the motor neurons are more frequent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The I113T mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/16\">",
"       16",
"      </a>",
"      ] is the second most common type, accounting for 16 percent of SOD1 mutations. This mutation has variable penetrance that can be low [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/23\">",
"       23",
"      </a>",
"      ]. The mean age of onset is 59 years. The clinical course is variable, ranging from quite rapid progression and death within two years, to very slow progression that can span 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Both upper and lower motor neuron findings occur. Posterior column involvement has been reported in one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Families with the A4T mutation in the SOD1 gene have a variable onset and duration. In one large kindred, the age of onset ranged from 32 to 60 years, with a mean of 46 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/27\">",
"       27",
"      </a>",
"      ]. Weakness in the legs was the most frequent early symptom, and there was a predominance of lower motor neuron signs. Bulbar and respiratory muscle involvement occurred in all individuals. The mean time from onset of symptoms to death was 14 months. One man with onset at age 37 had a more slowly developing form and was alive but severely affected 76 months after diagnosis. With this one exception, the severity was similar to that of the A4V mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 17 patients from three Japanese ALS1 families with the SOD1 H46R heterozygous mutation, the age of disease onset ranged from 32 to 60 years (average 44.3), the age of death ranged from 46 to older than 88 years (average 59 years), and the mean disease duration was greater than 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/28\">",
"       28",
"      </a>",
"      ]. The initial symptom was distal leg weakness in all patients. This relatively slow disease progression is in keeping with the clinical observation that bulbar involvement was minimal in these families; only 1 out of the 12 reported patients had tongue atrophy. Dementia was uniformly absent in these patients.",
"     </li>",
"     <li>",
"      Another report described three members of a familial ALS1 pedigree with a rare A89V SOD1 mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/29\">",
"       29",
"      </a>",
"      ]. This mutation is characterized by incomplete penetrance, variable age of onset, and an associated painful sensory neuropathy. In these three patients the disease onset was late in two and early in one. The early-onset patient was a 15-year-old male who presented with a one-year history of a progressive bilateral symmetric leg and arm weakness. The weakness was associated with sporadic cramps and fasciculations in the limbs and chest muscles but no bulbar involvement. On exam, he had brisk jaw reflexes, weak neck flexion and extension, bilateral weakness and atrophy of the upper and lower extremities, increased tone, hyperactive deep tendon reflexes, and a left Babinski response.",
"     </li>",
"     <li>",
"      In a report involving 20 patients, the G93C mutation was associated with a purely lower motor neuron phenotype and absence of bulbar involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/30\">",
"       30",
"      </a>",
"      ]. The mean age of onset was 46 years and disease progression was slow, with an average survival of nearly 13 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SOD1 mutations, usually those that can have low penetrance, can be seen in sporadic ALS. The most common of these are the I113T and D90A mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/23,26,31\">",
"     23,26,31",
"    </a>",
"    ]. In addition, rare cases of autosomal recessive familial ALS have been associated with double doses of the D90A mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/32\">",
"     32",
"    </a>",
"    ], and autosomal dominant familial ALS has been reported in patients who are heterozygotes for D90A [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ALS3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS3 has been linked to chromosome 18q21 in a single large French kindred [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/34\">",
"     34",
"    </a>",
"    ]. The average age of onset was 43 years. Leg onset was most common. Both upper and lower motor neuron signs occurred. Other central nervous system pathways were not involved. The mean life expectancy was five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ALS4 (SETX gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS4 is a juvenile form with an average age of onset in the second decade [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. It has been linked to the SETX gene on chromosome 9q34 coding for senataxin, a DNA and RNA helicase. It most commonly begins with distal weakness and atrophy of the hands and feet. Proximal weakness occurs later. Upper motor neuron signs occur, but bulbar involvement is uncommon. The clinical course is extremely slow. Progression to wheelchair use does not occur until the fifth or sixth decades. Minor sensory changes can occur in older individuals.",
"   </p>",
"   <p>",
"    Pathologically, the disorder is characterized by loss of upper and lower motor neurons as well as dorsal root ganglion neurons and posterior column fiber loss. Recessive mutations in SETX have been linked to inherited ataxia and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ALS6 (FUS gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the FUS gene (fused in sarcoma gene, also known as the TLS gene) on chromosome 16 have been linked to familial ALS6 in multiple families from diverse ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The phenotype is notable for onset at an average age of 45 years, with an average survival of 33 to 41 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, there is a wide variation in the duration of symptoms, with one reported patient surviving for 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/41\">",
"     41",
"    </a>",
"    ]. In a series of 18 patients, the onset was cervical more often than lumbar or bulbar [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/40\">",
"     40",
"    </a>",
"    ]. FUS mutations have also been identified in a few patients with familial ALS and frontotemporal lobe dementia or parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/41\">",
"     41",
"    </a>",
"    ]. In cases in which pathologic specimens were obtained, there was severe lower motor neuron loss in the spinal cord and to a lesser degree in the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FUS mutations are estimated to occur in 3 to 5 percent of familial ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/39-42\">",
"     39-42",
"    </a>",
"    ], similar to or possibly greater than the frequency of TARDBP mutations and less than the frequency of SOD1 or C9ORF72 mutations.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     FUS/TLS",
"    </span>",
"    protein is normally found in the nucleus, where it is involved in transcription regulation, RNA splicing, and RNA transport [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Thus, it is functionally similar to the TARDBP gene described below. Furthermore, cellular expression studies reveal that mutant forms of FUS have aberrant localization in the cytoplasm of neurons, similar to the pathology of TARDBP in familial ALS. These findings suggest that both FUS and TARDBP share a common pathogenic mechanism related to impaired RNA metabolism. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'ALS10 (TARDBP gene)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ALS7",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS7 has been linked to chromosome 20p13 in a single family [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/43\">",
"     43",
"    </a>",
"    ]. The mean onset was in the sixth decade, with a mean life expectancy of three years after onset. It is characterized by both upper and lower motor neuron signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ALS8 (VAPB gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS8 was initially linked to chromosome 20q13.33 in a single Brazilian family [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/44\">",
"     44",
"    </a>",
"    ]. It is characterized by onset in the third to the fifth decade with manifestations that include cramps, fasciculations, and at times lower motor neuron weakness. Upper motor neuron findings are less common. Some individuals manifest sensory loss, a postural tremor, or both. The course is slowly progressive. The cause is a missense mutation in the VAPB gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/45\">",
"     45",
"    </a>",
"    ]. The same VAPB mutation has been identified in additional families with clinically heterogeneous types of motor neuron disease, including ALS8, typical severe ALS with rapid progression, and late-onset spinal muscular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ALS9 (ANG gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missense mutations in the ANG gene coding for the protein angiogenin have been identified in Irish, Scottish, and Scandinavian individuals, some with and some without a dominant family history of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Mutations in ANG result in functional loss of angiogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/48\">",
"     48",
"    </a>",
"    ]. The angiogenin protein promotes vascularization of tissue and is required for the activity of vascular endothelial growth factor (VEGF).",
"   </p>",
"   <p>",
"    The clinical course associated with ANG mutations is that of progressive upper and lower motor neuron disease with a wide range of onset age and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The frequency of bulbar onset, about 50 percent, is greater than that of sporadic ALS. One patient with an ANG mutation initially presented with parkinsonism, followed five years later by manifestations of upper and lower motor neuron disease and features characteristic of frontotemporal dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ALS10 (TARDBP gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TAR DNA binding protein 43 (TDP-43) is a major component of ubiquinated inclusions in sporadic ALS, frontotemporal dementia (FTD) with",
"    <span class=\"nowrap\">",
"     ubiquitin-positive/tau-negative",
"    </span>",
"    inclusions, ALS with FTD, and familial ALS (with the exception of SOD1-related familial ALS1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Intracellular inclusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the TARDBP gene on chromosome 1p36.22 that encodes TDP-43 appear to be a cause of autosomal dominant familial ALS10, and may be a rare cause of sporadic ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. In one study, mutations in the TARDBP gene were identified in 9 of 200 patients with ALS, including three with a family history of ALS, and none of 365 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/53\">",
"     53",
"    </a>",
"    ]. In other reports, TARDBP mutations were found in 5 to 6 percent of families with non-SOD1 familial ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/18,52,54\">",
"     18,52,54",
"    </a>",
"    ]. Although the phenotype is variable, the clinical features of ALS in patients with TARDBP mutations compared with patients who have sporadic ALS include a greater likelihood for earlier onset, upper limb onset, and slower progression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/55\">",
"     55",
"    </a>",
"    ]. Some patients develop cognitive impairment or frontotemporal dementia. Other studies have identified TARDBP mutations in apparently sporadic and familial forms of frontotemporal lobe degeneration with and without motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ALS11 (FIG4 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS11 is an autosomal dominant form of ALS caused by mutations in the FIG4 gene on chromosome 6q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that screened DNA from 473 patients (364 with sporadic ALS and 109 with familial ALS), mutations in the FIG4 gene were identified in nine patients (2 percent), including six with sporadic ALS and three with familial ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/57\">",
"     57",
"    </a>",
"    ]. The protein encoded by FIG4 is a phosphoinositide 5-phosphatase that regulates a signaling lipid involved with membrane vesicle trafficking.",
"   </p>",
"   <p>",
"    Charcot-Marie-Tooth disease type 4J (CMT4J) is an allelic disorder caused by FIG4 mutations. The phenotype of CMT4J is notable for autosomal recessive inheritance, early childhood to adult onset, and involvement of both motor and sensory neurons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'CMT 4'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H161409026\">",
"    <span class=\"h2\">",
"     ALS12 (OPTN gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations within the OPTN gene are the cause of ALS12, as first identified in two Japanese families [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/58\">",
"     58",
"    </a>",
"    ]. Age of onset was 33 to 54 years and progression was slow. Later reports identified OPTN mutations in 1 to 2 percent of familial ALS and 0 to 3.5 percent of sporadic ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233524289\">",
"    <span class=\"h2\">",
"     ALS13 (ATXN2 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence suggests an association between intermediate length polyglutamine expansions in the ataxin 2 gene (ATXN2) and increased risk of ALS. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Genetic susceptibility in sporadic ALS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246948\">",
"    <span class=\"h2\">",
"     ALS14 (VCP gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in the valosin-containing protein gene (VCP) was first identified in an Italian family as the cause of ALS14 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/61\">",
"     61",
"    </a>",
"    ]. Additional VCP mutations have since been identified in other familial ALS cases, suggesting that VCP mutations are responsible for 1 to 2 percent of familial ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in VCP are also the cause of an autosomal dominant familial syndrome characterized by inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. There is mounting evidence that the spectrum of IBMPFD includes familial ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. The valosin-containing protein is implicated in numerous cellular functions, including pathways involved in ubiquitin-dependent protein degradation and autophagy. Mutant VCP may act by disrupting autophagy, resulting in the deposition of TDP-43 inclusions within the cytoplasm of affected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Intracellular inclusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10539001\">",
"    <span class=\"h2\">",
"     PFN1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the profilin 1 gene (PFN1) located on chromosome region 17p13.2 have been found in seven families with ALS displaying an autosomal dominant mode of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/66\">",
"     66",
"    </a>",
"    ]. The phenotype is notable for limb onset of ALS in middle age (average 45 years). The profilin 1 protein regulates actin polymerization and has multiple other cellular functions. Mutant profilin 1 may play a role in ALS pathogenesis on the basis of reduced levels of bound actin, inhibition of axon growth, and a propensity to form intracellular aggregates compared with wild-type profilin 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233525762\">",
"    <span class=\"h2\">",
"     CHMP2B-related ALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have associated mutations in the chromatin modifying protein 2b gene (CHMP2B gene) in both sporadic and dominantly inherited disorders referred to as chromosome 3-linked frontotemporal dementia (FTD3). While predominately associated with FTD3, late-onset (seventh to eighth decades) bulbar ALS with and without FTD has also been associated with CHMP2B mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233525093\">",
"    <span class=\"h2\">",
"     DAO gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in the D-amino acid oxidase gene (DAO) on chromosome region 12q24 has been associated with classic adult-onset familial ALS in a three-generational kindred from England [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/69\">",
"     69",
"    </a>",
"    ]. Features included upper and lower motor neuron involvement and bulbar signs but no cognitive impairment. The mean age at time of death was 44 years (range 42 to 55 years).",
"   </p>",
"   <p>",
"    D-amino acid oxidase is a flavoprotein that catalyzes the oxidative deamination of D-serine, a coagonist in the activation of the N-methyl-D-aspartate glutamate receptor subtype. The R199W DAO mutation identified in this study causes a loss of enzyme activity, which could lead to cell death via excitotoxicity from enhanced NMDA receptor activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233525261\">",
"    <span class=\"h2\">",
"     NEFH gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS linked to a mutation of the neurofilament heavy chain gene (NEFH) located on chromosome 22q12.1-q13.1 has been noted in a Scandinavian kindred [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/70\">",
"     70",
"    </a>",
"    ]. Variable features included monomelic amyotrophy, dementia, and bulbar dysfunction. One percent of sporadic ALS patients have been reported to have a mutation of the NEFH gene. Its role in the disease is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AUTOSOMAL RECESSIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recessively inherited familial amyotrophic lateral sclerosis includes ALS2 and ALS5. In autosomal recessive inheritance, a mutation in both copies of a gene is necessary in order for an individual to develop the condition. Typically, parents of an affected individual do not have the condition themselves, but are obligate carriers for the mutation. The siblings of an individual with an autosomal recessive condition have the highest recurrence risk. Siblings have a 25 percent likelihood of inheriting both copies of the gene with the mutation and developing ALS, a 50 percent likelihood of being an unaffected carrier for the condition, and a 25 percent likelihood of being an unaffected non-carrier for the condition. Unless an individual&rsquo;s partner is also a carrier for the same disease gene, all children of an individual with autosomal recessive ALS will be unaffected carriers of the condition. In autosomal recessive inheritance, there may be no family history of the condition in previous generations because a single copy of a gene mutation may be passed silently through a family.",
"   </p>",
"   <p>",
"    The ALS2 and SPG11 genes are inherited in an autosomal recessive pattern. Additionally, certain mutations in the SOD1 gene can be inherited in an autosomal recessive pattern. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'ALS1 (SOD1 gene)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ALS2 (ALS2 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS2 is caused by a mutation in exons 3 or 4 of the ALS2 gene coding for Alsin, a putative GTPase regulatory protein, on chromosome 2q33 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. The mean age of onset is in the first decade. Clinical features involve the development of upper motor neuron signs in the face and lower limbs, greater than in the upper limbs. Mild lower motor neuron findings develop slowly in the distal legs, more so than the arms. The course is markedly slow with note of difficulty walking in the fifth decade. An exception is the report of a patient with disease onset by age two and rapid progression to anarthria and wheelchair-bound status by age 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A deletion in exon 9 of the Alsin gene is responsible for recessively inherited childhood-onset primary lateral sclerosis (PLS), at times associated with gaze paresis. Frame shift mutations in various locations within the Alsin gene that produce a premature stop codon have been associated with recessively inherited infantile-onset familial spastic paraparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/71,75\">",
"     71,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ALS5 (SPG11 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS5, the most common form of autosomal recessive familial ALS, has been linked to mutations of the SPG11 gene on chromosome 15q15-q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The onset is in the second decade and is characterized by the development of lower motor neuron signs that exceed the upper motor neuron findings. Distal involvement is usually greater than proximal, and arms are usually involved more than legs. Bulbar involvement occurs late.",
"   </p>",
"   <p>",
"    Mutations involving SPG11 are also the cause of hereditary spastic paraplegia with a thin or atrophied corpus callosum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/78\">",
"     78",
"    </a>",
"    ]. However, the clinical features of patients with ALS5 and SPG11 mutations differ from those associated with hereditary spastic paraplegia due to the presence of bulbar symptoms, upper motor neuron involvement, and pathologic manifestations of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, the patients with familial ALS5 have not developed the corpus callosum thinning, ocular abnormalities, cognitive deficits, or psychiatric problems that are observed in SPG11-related hereditary spastic paraplegia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H29#H29\">",
"     \"Disorders affecting the spinal cord\", section on 'Hereditary spastic paraplegias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29081274\">",
"    <span class=\"h1\">",
"     X-LINKED DOMINANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In X-linked dominant inheritance, the gene responsible for the condition is located on the X chromosome and only one copy of the gene with the mutation is necessary to cause the disease. Therefore, unlike X-linked recessive inheritance, both males and females may be affected. If a father has an X-linked dominant condition all of his daughters will inherit the disease and none of his sons will inherit the disease. If a mother has an X-linked dominant disease, there is a 50 percent likelihood that her daughters or her sons will inherit the condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233524747\">",
"    <span class=\"h2\">",
"     ALS15 (UBQLN2 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In five unrelated families, a form of dominantly-inherited ALS with reduced penetrance in women was linked to mutations of the UBQLN2 gene located at Xp11.21 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/79\">",
"     79",
"    </a>",
"    ]. The age of onset ranged from 16 to 71 years and was earlier in males, while mean disease duration was approximately four years and was similar in males and females. A frontotemporal lobar type of dementia accompanied some cases of ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108656424\">",
"    <span class=\"h1\">",
"     INDETERMINATE INHERITANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inheritance pattern is not yet clear for ALS associated with SQSTM1 mutations, as reported in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106791803\">",
"    <span class=\"h2\">",
"     SQSTM1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following upon the knowledge that protein degradation pathways are implicated in ALS and frontotemporal lobe degeneration (FTD), two groups screened large cohorts of patients with ALS and FTD and found mutations in the sequestosome 1 (SQSTM1) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The SQSTM1 gene encodes for the p62 protein, which binds ubiquitin and is involved in protein degradation and autophagy. SQSTM1 mutations were noted in both familial and sporadic cases of ALS and FTD. While one study reports heterozygous inheritance consistent with dominant genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/80\">",
"     80",
"    </a>",
"    ] the other is silent on this subject [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/81\">",
"     81",
"    </a>",
"    ]. The precise role of this gene in the pathogenesis of ALS is not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GENETIC TESTING AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for specific ALS-causing mutations is most useful for establishing the diagnosis (particularly for juvenile or early-stage disease) and for assessing risk among family members of an affected relative with an established genetic cause (",
"    <a class=\"graphic graphic_table graphicRef61384 \" href=\"UTD.htm?35/41/36507\">",
"     table 1",
"    </a>",
"    ). In contrast, genetic testing for prognostic purposes in ALS is of limited value.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common use of genetic testing for ALS is to provide risk information and subsequent counseling for unaffected at-risk family members. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H18#H18\">",
"       \"Genetic counseling and testing\", section on 'Principles of genetic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In cases where the diagnosis is clear, genetic testing has little or no additional value in making the diagnosis of ALS and will not impact medical management or treatment options. In rare cases of early stage disease (ie, clinically suspected and clinically possible ALS by El Escorial criteria), with or without a family history of ALS, the discovery of an ALS related gene can change the diagnosis to clinically definite laboratory supported familial ALS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing may provide limited prognostic information, such as predicting rapid progression in individuals with the A4V SOD1 mutation. However, genetic testing should not be used for this purpose because the phenotypic variability seen in familial ALS makes such predictions unreliable at the level of individual cases.",
"     </li>",
"     <li>",
"      Genetic testing may play a role in making the diagnosis of Kennedy syndrome and late-onset Tay-Sachs disease, two genetic disorders that can mimic some of the clinical features of ALS. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Genetic testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A glossary of genetic terms is available in a table (",
"    <a class=\"graphic graphic_table graphicRef72267 \" href=\"UTD.htm?24/6/24685\">",
"     table 2",
"    </a>",
"    ) and, in an expanded form, in a separate topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233524905\">",
"    <span class=\"h2\">",
"     Recurrence risk within a family",
"    </span>",
"    &nbsp;&mdash;&nbsp;For familial ALS, the recurrence risk of ALS in a given family (ie, whether or not another family member will develop ALS) is estimated primarily by determining the inheritance pattern. The mode of inheritance in familial ALS can be autosomal dominant, autosomal recessive, or (rarely) X-linked. Autosomal dominant inheritance is the most common pattern of inheritance observed in hereditary ALS.",
"   </p>",
"   <p>",
"    The mode of inheritance is determined by analysis of the family history and the results of genetic testing if available. Thus, a detailed pedigree covering at least three generations should be obtained that includes the affected individual's parents, siblings, children, grandparents, aunts and uncles, nieces and nephews, and first cousins. Information to be collected should include current age, health status, age at death, cause of death, medical diagnoses, and any possible symptoms of ALS that may have gone undiagnosed.",
"   </p>",
"   <p>",
"    Of note, the family history may be falsely negative due to a number of factors, including failure to recognize the disorder in family members, death from other causes prior to ALS symptom onset, non-paternity, or late onset or reduced penetrance of the disease in affected family members.",
"   </p>",
"   <p>",
"    With sporadic ALS, it is generally believed that the recurrence risk of ALS is not significantly higher than the risk in the general population when there is only one family member affected with ALS. The recurrence risk would increase should another family member be diagnosed with ALS. The recurrence risk may be as high as 50 percent if there are multiple family members affected with ALS. However, the exact recurrence risk for ALS cannot be determined in the absence of a positive genetic test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455427516\">",
"    <span class=\"h2\">",
"     Who should be tested?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While any willing individual with ALS can have testing, a genetic cause is most likely to be found in those who have a family history of autosomal dominant disease or juvenile-onset ALS with suspected autosomal recessive inheritance. Genetic testing may also be useful in individuals with familial ALS who lack a clear family history consistent with an autosomal dominant disease, a situation that may occur because of reduced penetrance or limited information about important family members. However, the likelihood of identifying a mutation in a gene associated with ALS is reduced in this setting. As noted earlier, the most common use of genetic testing for ALS is to provide risk information and subsequent counseling for unaffected at-risk family members.",
"   </p>",
"   <p>",
"    In patients with a family history suggesting autosomal dominant inheritance, genetic testing can provide prognostic information. As examples, the finding of a C9ORF72 mutation (see",
"    <a class=\"local\" href=\"#H1808661\">",
"     'C9ORF72 gene'",
"    </a>",
"    above) implies a high risk for the development of comorbid frontotemporal dementia with ALS, while the finding of the A4V SOD1 mutation (see",
"    <a class=\"local\" href=\"#H3\">",
"     'ALS1 (SOD1 gene)'",
"    </a>",
"    above) augurs a poor prognosis due to rapid progression and an average life expectancy of only 1.5 years after the onset of symptoms. However, the impact of a positive genetic test on clinical care in patients with ALS is limited, since the treatment options are few and management is mainly symptomatic.",
"   </p>",
"   <p>",
"    There may be clinical trials available to patients with specific ALS genotypes. An updated list of clinical trials is available online at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     ClinicalTrials.gov",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Individuals with apparently sporadic ALS may also pursue genetic testing, as approximately 10 percent or more of apparently sporadic cases of ALS have a mutation in one of the genes currently associated with familial ALS, including TARDBP, C9ORF72, SOD1, ANG, FUS, OPTN, and SETX, or in one of the genes likely to be susceptibility factors for ALS, including ATXN2 and SMN1. In these cases, the lack of family history suggests either low penetrance or a de novo mutation of a gene associated with ALS. In addition, the absence of family history with apparently sporadic ALS makes it difficult to quantify the risk of ALS for unaffected family members with the same mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Genetic susceptibility in sporadic ALS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anyone diagnosed with ALS or any adult with a family history of ALS who is considering genetic testing should first meet with a genetic counselor or a physician knowledgeable about familial ALS to discuss the genetic basis of the disease as well as the medical, psychological, and familial implications. Those pursuing testing should be informed of a number of issues and limitations of genetic testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predictive value of a positive genetic test can be limited by a number of factors, including lack of population-based data on penetrance (ie, the likelihood of developing disease given inheritance of a disease-causing mutation) and variable expressivity (ie, phenotypic variations in the way the disease is expressed). Thus, the ability of the genetic test to predict phenotype (ie, the clinical validity) may be limited.",
"     </li>",
"     <li>",
"      The impact of a positive genetic test for ALS for the purpose of clinical care is essentially nil, since the treatment options are limited and management is mainly symptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional concerns that should be addressed by genetic counseling include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The meaning of a positive or negative test, including the slight possibility of false positive or negative results",
"     </li>",
"     <li>",
"      Psychosocial issues related to family dynamics",
"     </li>",
"     <li>",
"      Disclosing genetic information to at-risk family members",
"     </li>",
"     <li>",
"      The possibility of genetic discrimination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are explored in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H20#H20\">",
"     \"Genetic counseling and testing\", section on 'Penetrance, ascertainment bias, and variable expression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetic counseling and testing\", section on 'Validity and utility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link&amp;anchor=H22#H22\">",
"     \"Genetic counseling and testing\", section on 'Ethical, legal, and psychosocial issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In families where a mutation in a gene associated with ALS has not been previously identified, testing is most likely to identify pathogenic variants in the affected family members with ALS, rather than at-risk members. Therefore, it is preferable to begin searching for variants by gene sequencing in affected members, and then subsequently perform direct genotyping of identified pathogenic variants in potentially at-risk individuals. Once a disease-causing mutation has been identified, other family members may choose to be tested for the same mutation regardless of whether or not they have symptoms. (See",
"    <a class=\"local\" href=\"#H29079546\">",
"     'Unaffected family members'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For ethical reasons, genetic testing is not appropriate for children and adolescents at risk for adult-onset ALS. There are a number of potential risks (eg, lack of autonomy, discrimination, stigmatization, anxiety) associated with the predictive testing of minors and there is no compelling benefit because preventive treatment is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079488\">",
"    <span class=\"h2\">",
"     How the test is done",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing can be done on a blood, saliva, or tissue sample. The sample is then analyzed for mutations in the specific gene(s) of interest.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full gene sequencing is considered the gold standard for identifying both known and novel mutations in a gene and involves analyzing the entire coding region of the gene. Full gene sequencing will detect most mutations in the tested gene.",
"     </li>",
"     <li>",
"      Targeted mutation analysis (genotyping) involves testing for a specific mutation or set of mutations in the gene of interest, and will only detect mutations in the tested region(s) of the gene, but will not identify all mutations in the gene of interest. Targeted mutation analysis is often used for predictive testing in at-risk family members to identify mutations already known to exist in affected family members (ie, as identified through sequencing).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079495\">",
"    <span class=\"h2\">",
"     Genes to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical genetic testing for inherited (familial) forms of ALS is available to look for causative mutations in SOD1, TARDBP, FUS, FIG4, ANG, Alsin (ALS2), VAPB, OPTN, and SETX genes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/48/16138/abstract/83\">",
"     83",
"    </a>",
"    ]. Approximately 13 to 20 percent of familial ALS is linked to mutations in the SOD1 gene, and an even higher percentage is linked to mutations in the C9ORF72 gene. In addition, mutations in the FUS gene, ANG gene, TARDBP gene, and FIG4 gene may account for as much as 5, 2, 5, and 3 percent of familial ALS, respectively. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'ALS1 (SOD1 gene)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1808661\">",
"     'C9ORF72 gene'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'ALS6 (FUS gene)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'ALS9 (ANG gene)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'ALS10 (TARDBP gene)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'ALS11 (FIG4 gene)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Testing is commercially available for most of these genes, but is usually pursued only if there is a clear family history of autosomal dominant disease.",
"   </p>",
"   <p>",
"    Ideally, it is best to order a genetic panel for ALS that includes five of the most common genes that are available for clinical genetic testing: SOD1, TARDBP, FUS, FIG4, and ANG genes. Clinical genetic testing for C9ORF72 will likely be available sometime in 2012. Genetic testing can be done in a step-wise manner if a full panel cannot be ordered for financial or insurance reasons. In the absence of a personal or family history of frontotemporal dementia, the highest yield test to order is SOD1, since mutations in the SOD1 gene cause approximately 13 to 20 percent of familial cases of ALS and SOD1 mutations do not cause FTD. If SOD1 is negative, the other genes may be ordered either in the order of frequency associated with familial ALS or by the presence of clinical features. As an example, if the patient has spinal onset ALS with mainly lower motor neuron signs and an absence of bulbar signs, TARDBP may be the best gene to order next.",
"   </p>",
"   <p>",
"    In the setting of a personal or family history of frontotemporal dementia, testing for an expanded hexanucleotide repeat in the C9ORF72 gene should be obtained once this test is clinically available. In the meantime, we suggest starting genetic testing with TARDBP, FUS, ANG, or FIG4 first and SOD1 last.",
"   </p>",
"   <p>",
"    If the patient has juvenile-onset ALS, genetic testing for SPG11, SETX and ALS2 may be appropriate. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Autosomal recessive'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079502\">",
"    <span class=\"h2\">",
"     Laboratories offering testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on laboratories offering genetic testing for ALS is available online at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests\">",
"     GeneTests",
"    </a>",
"    . The",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests\">",
"     GeneTests",
"    </a>",
"    website is a publicly funded medical genetics information resource that lists available genetic tests for thousands of conditions, with a directory of certified clinical laboratories specializing in genetic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079509\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To properly interpret genetic test results for ALS genes, it is necessary to know whether the person who is being tested has ALS and whether a mutation in the family has already been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079516\">",
"    <span class=\"h3\">",
"     Patients with ALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For individuals with ALS who do",
"    <strong>",
"     not",
"    </strong>",
"    already have a known familial mutation, there are three possible types of test results as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test result means that the individual has a disease-causing (pathogenic) mutation or mutations and that the cause of ALS observed in the family has been identified. A positive result also further defines the risk to develop ALS for other family members. Interpretation of the ALS risk to other family members depends on the mode of inheritance of the gene with the mutation(s). (See",
"      <a class=\"local\" href=\"#H233524905\">",
"       'Recurrence risk within a family'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A negative test result means that the individual does not have a mutation in the tested gene or genes. However, a negative result does not rule out entirely the possibility of a genetic cause for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Not all genes may have been tested. For example, if only testing for SOD1 was ordered, a negative result would not rule out the possibility of a mutation in TARDBP, FUS, FIG4, or ANG.",
"     </li>",
"     <li>",
"      Not all base positions of a targeted gene may have been adequately tested. For sequencing, this may occur if the assay was designed to target coding regions only, ignoring functional noncoding regions (such as regulatory or intronic regions). Also, gene coverage may be incomplete due to assay failure. In these instances, the individual may harbor pathogenic variants that are simply missed. In the context of targeted genotyping (testing of a limited number of variants) one can only confidently report a negative result for those specific variants tested. For example, a negative result from genotyping of the most common SOD1 mutation in North America, A4V, only excludes that variant, but does not rule out any of the other 139 known SOD1 mutations.",
"     </li>",
"     <li>",
"      Not all genetic causes of ALS have been identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An indeterminate result means that a change was found in the genetic sequence of the gene, but the laboratory cannot yet make a clear determination as to whether it is a pathogenic mutation or a benign polymorphism. Benign polymorphisms are common variations in DNA that do not cause disease. An indeterminate result is sometimes called a variant of unknown significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With an indeterminate result, it is suggested that the mutation be tracked through the family, which involves testing multiple affected and unaffected family members. However, tracking a mutation through a family for an adult-onset condition can be challenging; when an unaffected family member tests positive for the mutation it is not clear whether this individual will develop ALS in the future or if the mutation is benign. It can take years to determine whether or not a variant of unknown significance is pathogenic.",
"   </p>",
"   <p>",
"    For individuals with a diagnosis of ALS who are part of a family with a known familial mutation, a positive test result confirms that the individual did inherit the known familial mutation and supports that mutation as the cause of ALS for the individual. A negative result means that the individual did not inherit the known familial mutation; therefore the cause of ALS for the individual is unknown. In this scenario, the individual would be considered to have sporadic ALS. This is known as a phenocopy. A second sample may be sent for genetic testing to confirm the result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079546\">",
"    <span class=\"h3\">",
"     Unaffected family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unaffected family members considering genetic testing for ALS are often concerned about possible symptoms of ALS. In such cases, a neurologic evaluation to look for evidence of ALS and a discussion with a trained genetic counselor can help alleviate concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233524177\">",
"    <span class=\"h4\">",
"     Known family mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing an asymptomatic person who is at risk for inheriting a known family mutation is called presymptomatic (or predictive) testing. For presymptomatic testing, a mutation must have been first identified in the family so that the clinician knows the appropriate test to order. The possible test results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test result means that the individual has a pathogenic mutation and is at risk to develop ALS. The probability that the individual will develop symptoms of ALS will depend on factors such as penetrance and expressivity. Penetrance and expressivity information is available for some SOD1 mutations but is limited for the other ALS genes.",
"     </li>",
"     <li>",
"      A negative test result means that the individual does not have a mutation in the tested gene and is not at risk for the familial form of ALS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Family members may have different opinions about whether or not to pursue presymptomatic testing, as this is a very personal decision that can be confusing and emotionally difficult. Meeting with a trained genetic counselor and a psychological evaluation are recommended to help the individual throughout the testing process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233524184\">",
"    <span class=\"h4\">",
"     No known family mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presymptomatic (or predictive) genetic testing for an unaffected individual with a family history of ALS but no known familial mutation is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because it is difficult to determine the appropriate test to order and interpret the meaning of negative or indeterminate genetic test results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A negative test result would mean that the individual did",
"      <strong>",
"       not",
"      </strong>",
"      have a mutation in the tested gene or genes. However, this finding would",
"      <strong>",
"       not",
"      </strong>",
"      rule out the possibility that they have inherited a genetic form of ALS. In this situation there are three possible scenarios to explain the history of ALS observed in the family:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is due to a mutation in one of the tested genes and the individual did not inherit the mutation. The patient is not at an increased risk of developing ALS.",
"     </li>",
"     <li>",
"      It is due to an unknown gene and it is unknown if the individual inherited the mutation. The patient may be at an increased risk of developing ALS.",
"     </li>",
"     <li>",
"      It is due to environmental factors and is not genetic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An indeterminate result means that a change was found in the genetic sequence of the gene, but the laboratory cannot make a clear determination as to whether it is a pathogenic mutation or a benign polymorphism. This individual may or may not develop ALS in the future.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079596\">",
"    <span class=\"h2\">",
"     Differences between clinical and research genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of clinical genetic testing is primarily for diagnosis or presymptomatic genetic testing (",
"    <a class=\"graphic graphic_table graphicRef61384 \" href=\"UTD.htm?35/41/36507\">",
"     table 1",
"    </a>",
"    ). The testing is performed in an accredited laboratory. A report of the results is generated and is part of the patient's official medical record. There is a charge for clinical testing, which may or may not be covered by insurance.",
"   </p>",
"   <p>",
"    The purpose of research genetic testing is to discover and to better understand the genetic factors of ALS. Patient identifiers and information remain confidential and results do not become part of the patient's official medical record. There is no fee when participating in a research study, and generally results are not returned to participants. Many individuals choose to participate in research genetic testing to help advance the ALS field for the benefit of others with or without ALS now and for future generations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29079459\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial amyotrophic lateral sclerosis (familial ALS) is phenotypically and genetically heterogeneous. In most individual cases, it may be difficult to determine on clinical grounds alone if ALS is familial or sporadic, especially at the onset of disease. The presence of atypical features such as young age of onset, sensory loss, a positive family history of ALS, other neurodegenerative disorders, and dementia should alert the clinician to the possibility of familial ALS. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of familial ALS cases follow an autosomal dominant inheritance pattern. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Autosomal dominant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An expanded hexanucleotide repeat in the C9ORF72 gene appears to be the cause of 24 to 47 percent of familial forms of ALS. Another 12 to 20 percent of familial ALS cases are caused by SOD1 gene mutations. In addition, mutations in the FUS gene, ANG gene, TARDBP gene, and FIG4 gene may account for as much as 5, 2, 5, and 3 percent of familial ALS, respectively. (See",
"      <a class=\"local\" href=\"#H1808661\">",
"       'C9ORF72 gene'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'ALS1 (SOD1 gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'ALS6 (FUS gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'ALS9 (ANG gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'ALS10 (TARDBP gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'ALS11 (FIG4 gene)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less common forms of autosomal dominant familial ALS include ALS 3, ALS4, ALS7, ALS8, ALS12, ALS14, and ALS caused by mutations of the PFN1, CHMP2B, DAO and NEFH genes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ALS3'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'ALS4 (SETX gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'ALS7'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'ALS8 (VAPB gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H161409026\">",
"       'ALS12 (OPTN gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H246948\">",
"       'ALS14 (VCP gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10539001\">",
"       'PFN1 gene'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H233525762\">",
"       'CHMP2B-related ALS'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H233525093\">",
"       'DAO gene'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H233525261\">",
"       'NEFH gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autosomal recessive forms of familial ALS are associated with mutations of the ALS2 and SPG11 genes. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Autosomal recessive'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'ALS2 (ALS2 gene)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'ALS5 (SPG11 gene)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An X-linked dominant form of familial ALS is associated with UBQLN2 gene mutations. (See",
"      <a class=\"local\" href=\"#H29081274\">",
"       'X-linked dominant'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H233524747\">",
"       'ALS15 (UBQLN2 gene)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical genetic testing for inherited (familial) forms of ALS is available to look for causative mutations in a number of genes. The most common use of genetic testing for ALS is to provide risk information and subsequent counseling for unaffected at-risk family members. To properly interpret genetic test results for ALS genes, it is necessary to know whether the person being tested has ALS and whether a mutation in the family has already been identified. The recurrence risk of ALS in a given family (ie, whether or not another family member will develop ALS) is estimated primarily by determining the inheritance pattern. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Genetic testing and counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/1\">",
"      Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:623.",
"     </a>",
"    </li>",
"    <li>",
"     Falcone D, McCluskey L. Unpublished data. 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/3\">",
"      DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/4\">",
"      Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/5\">",
"      Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/6\">",
"      Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012; 11:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/7\">",
"      Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/8\">",
"      Rutherford NJ, DeJesus-Hernandez M, Baker MC, et al. C9ORF72 hexanucleotide repeat expansions in patients with ALS from the Coriell Cell Repository. Neurology 2012; 79:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/9\">",
"      van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 2012; 79:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/10\">",
"      Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006; 66:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/11\">",
"      Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006; 129:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/12\">",
"      Valdmanis PN, Dupre N, Bouchard JP, et al. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol 2007; 64:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/13\">",
"      Le Ber I, Camuzat A, Berger E, et al. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 2009; 72:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/14\">",
"      Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000; 284:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/15\">",
"      Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 2007; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/16\">",
"      Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/17\">",
"      Siddique N, Siddique T. Genetics of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/18\">",
"      Millecamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet 2010; 47:554.",
"     </a>",
"    </li>",
"    <li>",
"     ALS online genetics database. file://alsod.iop.kcl.ac.uk/Als/index.aspx (Accessed on September 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/20\">",
"      Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/21\">",
"      Ratovitski T, Corson LB, Strain J, et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet 1999; 8:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/22\">",
"      Cudkowicz ME, McKenna-Yasek D, Chen C, et al. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998; 43:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/23\">",
"      Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/24\">",
"      Gellera C. Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/25\">",
"      Gellera C, Castellotti B, Riggio MC, et al. Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscul Disord 2001; 11:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/26\">",
"      Hays AP, Naini A, He CZ, et al. Sporadic amyotrophic lateral sclerosis and breast cancer: Hyaline conglomerate inclusions lead to identification of SOD1 mutation. J Neurol Sci 2006; 242:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/27\">",
"      Aksoy H, Dean G, Elian M, et al. A4T mutation in the SOD1 gene causing familial amyotrophic lateral sclerosis. Neuroepidemiology 2003; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/28\">",
"      Arisato T, Okubo R, Arata H, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol 2003; 106:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/29\">",
"      Rezania K, Yan J, Dellefave L, et al. A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset, incomplete penetrance and a sensory neuropathy. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/30\">",
"      R&eacute;gal L, Vanopdenbosch L, Tilkin P, et al. The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch Neurol 2006; 63:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/31\">",
"      Andersen PM, Nilsson P, Ala-Hurula V, et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995; 10:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/32\">",
"      Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119 ( Pt 4):1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/33\">",
"      Robberecht W, Aguirre T, Van den Bosch L, et al. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology 1996; 47:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/34\">",
"      Hand CK, Khoris J, Salachas F, et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002; 70:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/35\">",
"      Chance PF, Rabin BA, Ryan SG, et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998; 62:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/36\">",
"      Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004; 74:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/37\">",
"      Asaka T, Yokoji H, Ito J, et al. Autosomal recessive ataxia with peripheral neuropathy and elevated AFP: novel mutations in SETX. Neurology 2006; 66:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/38\">",
"      Chen YZ, Hashemi SH, Anderson SK, et al. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol Dis 2006; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/39\">",
"      Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/40\">",
"      Vance C, Rogelj B, Hortob&aacute;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/41\">",
"      Yan J, Deng HX, Siddique N, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 2010; 75:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/42\">",
"      Hewitt C, Kirby J, Highley JR, et al. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2010; 67:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/43\">",
"      Sapp PC, Hosler BA, McKenna-Yasek D, et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet 2003; 73:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/44\">",
"      Nishimura AL, Mitne-Neto M, Silva HC, et al. A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. J Med Genet 2004; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/45\">",
"      Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/46\">",
"      Greenway MJ, Alexander MD, Ennis S, et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology 2004; 63:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/47\">",
"      Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006; 38:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/48\">",
"      Wu D, Yu W, Kishikawa H, et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol 2007; 62:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/49\">",
"      van Es MA, Diekstra FP, Veldink JH, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 2009; 72:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/50\">",
"      Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/51\">",
"      Yokoseki A, Shiga A, Tan CF, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 2008; 63:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/52\">",
"      Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 2008; 7:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/53\">",
"      Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/54\">",
"      K&uuml;hnlein P, Sperfeld AD, Vanmassenhove B, et al. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol 2008; 65:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/55\">",
"      Corcia P, Valdmanis P, Millecamps S, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology 2012; 78:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/56\">",
"      Borroni B, Archetti S, Del Bo R, et al. TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res 2010; 13:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/57\">",
"      Chow CY, Landers JE, Bergren SK, et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 2009; 84:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/58\">",
"      Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/59\">",
"      Del Bo R, Tiloca C, Pensato V, et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/60\">",
"      Belzil VV, Daoud H, Desjarlais A, et al. Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiol Aging 2011; 32:555.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/61\">",
"      Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/62\">",
"      Gonz&aacute;lez-P&eacute;rez P, Cirulli ET, Drory VE, et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology 2012; 79:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/63\">",
"      Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/64\">",
"      Nalbandian A, Donkervoort S, Dec E, et al. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci 2011; 45:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/65\">",
"      Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009; 187:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/66\">",
"      Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012; 488:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/67\">",
"      Gydesen S, Brown JM, Brun A, et al. Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology 2002; 59:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/68\">",
"      Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006; 67:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/69\">",
"      Mitchell J, Paul P, Chen HJ, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A 2010; 107:7556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/70\">",
"      Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/71\">",
"      Eymard-Pierre E, Lesca G, Dollet S, et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet 2002; 71:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/72\">",
"      Gros-Louis F, Meijer IA, Hand CK, et al. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann Neurol 2003; 53:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/73\">",
"      Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001; 29:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/74\">",
"      Kress JA, K&uuml;hnlein P, Winter P, et al. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann Neurol 2005; 58:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/75\">",
"      Gascon GG, Chavis P, Yaghmour A, et al. Familial childhood primary lateral sclerosis with associated gaze paresis. Neuropediatrics 1995; 26:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/76\">",
"      Hentati A, Ouahchi K, Pericak-Vance MA, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 1998; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/77\">",
"      Orlacchio A, Babalini C, Borreca A, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 2010; 133:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/78\">",
"      Stevanin G, Santorelli FM, Azzedine H, et al. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 2007; 39:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/79\">",
"      Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/80\">",
"      Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/81\">",
"      Rubino E, Rainero I, Chi&ograve; A, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012; 79:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/48/16138/abstract/82\">",
"      Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 1995; 57:1233.",
"     </a>",
"    </li>",
"    <li>",
"     Donkervoort S, Siddique T. Amyotrophic lateral sclerosis overview. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=als-overview (Accessed on October 10, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5176 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16138=[""].join("\n");
var outline_f15_48_16138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29079459\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H136713437\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOSOMAL DOMINANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1808661\">",
"      C9ORF72 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALS1 (SOD1 gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALS3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALS4 (SETX gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALS6 (FUS gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALS7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALS8 (VAPB gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALS9 (ANG gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ALS10 (TARDBP gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ALS11 (FIG4 gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H161409026\">",
"      ALS12 (OPTN gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233524289\">",
"      ALS13 (ATXN2 gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H246948\">",
"      ALS14 (VCP gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10539001\">",
"      PFN1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233525762\">",
"      CHMP2B-related ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233525093\">",
"      DAO gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233525261\">",
"      NEFH gene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AUTOSOMAL RECESSIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ALS2 (ALS2 gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ALS5 (SPG11 gene)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29081274\">",
"      X-LINKED DOMINANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233524747\">",
"      ALS15 (UBQLN2 gene)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108656424\">",
"      INDETERMINATE INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106791803\">",
"      SQSTM1 gene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GENETIC TESTING AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233524905\">",
"      Recurrence risk within a family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455427516\">",
"      Who should be tested?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29079488\">",
"      How the test is done",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29079495\">",
"      Genes to test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29079502\">",
"      Laboratories offering testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29079509\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29079516\">",
"      - Patients with ALS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29079546\">",
"      - Unaffected family members",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H233524177\">",
"      Known family mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H233524184\">",
"      No known family mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29079596\">",
"      Differences between clinical and research genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29079459\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/41/36507\" title=\"table 1\">",
"      Risks benefits genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/6/24685\" title=\"table 2\">",
"      Genetic terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_48_16139="Signs of nonessential tremor";
var content_f15_48_16139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms or signs suggestive of tremor other than essential tremor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Symptom or sign",
"      </td>",
"      <td class=\"subtitle1\">",
"       Likely differential diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unilateral tremor, leg tremor, rigidity, bradykinesia, rest tremor",
"      </td>",
"      <td>",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gait disturbance",
"      </td>",
"      <td>",
"       Parkinson disease, cerebellar tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Focal tremor",
"      </td>",
"      <td>",
"       Dystonic tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isolated head tremor with abnormal posture (head tilt or turning)",
"      </td>",
"      <td>",
"       Dystonic tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sudden or rapid onset",
"      </td>",
"      <td>",
"       Psychogenic tremor, toxic tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Current drug treatment that may cause or exacerbate tremor",
"      </td>",
"      <td>",
"       Drug-induced or toxic tremor",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permisssion from: Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(suppl 4):s7. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16139=[""].join("\n");
var outline_f15_48_16139=null;
var title_f15_48_16140="Split urine collection protocol";
var content_f15_48_16140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient instructions for performing a split urine collection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Introduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A \"split urine test\" is a method to determine whether the protein discovered in your urine is due to a condition called orthostatic proteinuria. This&nbsp;is a harmless condition that is not uncommon in young people. For reasons that are not well understood, some people leak protein into the urine when they are standing or sitting but not while they are lying down. The split urine test is a simple way to determine if this condition is present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The test requires that you collect all of your urine for 24 hours. Pick a day when this would be convenient for you. Males might want to buy an inexpensive urinal for easy collection; females should buy an inexpensive basin urinal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You also need two jugs and a funnel. One-half gallon plastic jugs, thoroughly rinsed, are adequate if jugs are not provided. Label the two jugs: (1) Daytime urine and (2) Nighttime urine, respectively.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Perform the following steps on the day that you are going to make the split urine collections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        When you first get up,",
"        <strong>",
"         discard",
"        </strong>",
"        the first morning urine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For the rest of the day,",
"        <strong>",
"         collect",
"        </strong>",
"        all of the urine each time you void. Put this urine into the Daytime urine jug. You should be as active as you normally are during the day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In the evening, lie down for&nbsp;",
"        <strong>",
"         two hours",
"        </strong>",
"        before you go to sleep. Just before sleeping, void for the last time during the day and add this urine to the Daytime jug. Lying down for two hours before the nighttime collection avoids contamination of the nighttime collection with urine formed during the day when you were upright.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The following morning (approximately eight hours after you went to sleep), collect the first-morning urine and put in the",
"        <strong>",
"         Nighttime",
"        </strong>",
"        urine jug.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Take the two jugs to the laboratory.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        We will notify you when we get the results.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16140=[""].join("\n");
var outline_f15_48_16140=null;
var title_f15_48_16141="FAB classification";
var content_f15_48_16141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    French-American-British (FAB) classification of acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FAB type",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Blasts, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Erythroid progenitors",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Morphology",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Cytochemistry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        All cells",
"       </td>",
"       <td class=\"subtitle2\">",
"        NEC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;90",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        Blasts resemble L2 variant of ALL; cytoplasmic granules and Auer rods are not seen.",
"       </td>",
"       <td>",
"        &lt;3 percent PXase+ or SBB+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;90",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;30 percent type 1 and type 2 blasts; &lt;10 percent differentiated myeloid cells; Auer rods seen in about 50 percent of cases",
"       </td>",
"       <td>",
"        &gt;3 percent PXase+ or SBB+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M2",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;30-89",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;30 percent type 1 and type 2 blasts; &gt;10 percent differentiated myeloid cells; Auer rods seen in about 70 percent of cases",
"       </td>",
"       <td>",
"        PXase+ SBB+ NSE+&lt;20 percent PAS-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M3",
"       </td>",
"       <td>",
"        &gt;30*",
"       </td>",
"       <td>",
"        &gt;30-89",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;20 percent abnormal hypergranular progranulocytes; blast count may be &lt;30 percent; Auer rods and faggot cells seen in virtually all cases",
"       </td>",
"       <td>",
"        PXase+ SBB+ PAS- NSE&plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M3V",
"       </td>",
"       <td>",
"        &gt;30*",
"       </td>",
"       <td>",
"        &gt;30-89",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;20 percent abnormal hypogranular progranulocytes; blast count may be &lt;30 percent; Auer rods and faggot cells seen in virtually all cases",
"       </td>",
"       <td>",
"        PXase+ SBB+ PAS- NSE&plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;30-79",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;20 percent promonocytes and monocytes; &gt;20 percent granulocytic cells; peripheral monocytosis (&gt;5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        ) &plusmn; elevated serum or urine lysozyme; Auer rods seen in about 65 percent of cases",
"       </td>",
"       <td>",
"        PXase+ &gt;20 percent NSE+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4eo",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;30-79",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;5 percent&nbsp;eosinophils and cells with mixed basophilic and eosinophilic granules, plus M4 features",
"       </td>",
"       <td>",
"        PXase+ &gt;20 percent NSE+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M5a",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;80",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;80 percent&nbsp;of nonerythroid cells are monoblasts; Auer rods usually not seen",
"       </td>",
"       <td>",
"        NSE+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M5b",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;80",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &gt;80 percent&nbsp;of nonerythroid cells are monocytes, promonocytes, and monoblasts; Auer rods can be seen in a minor population of myeloblasts (30 percent of cases)",
"       </td>",
"       <td>",
"        NSE+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;50",
"       </td>",
"       <td>",
"        Erythroid predominance and dysplasia; &gt;30 percent&nbsp;blasts among non-erythroid cells; Auer rods present in blasts in 60 percent&nbsp;of cases",
"       </td>",
"       <td>",
"        PAS+ (erythroid cells); blasts are PXase+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M7",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        Blasts with cytoplasmic blebbing &plusmn; platelet shedding; marrow fibrosis; Auer rods are not seen",
"       </td>",
"       <td>",
"        Platelet PXase+ on EM",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NEC: nonerythroid cells; PXase: peroxidase; SBB: Sudan black; NSA: nonspecific esterase; PAS: periodic acid-Schiff.",
"     <br>",
"      * Abnormal progranulocytes and blasts.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16141=[""].join("\n");
var outline_f15_48_16141=null;
var title_f15_48_16142="Esophageal stricture Ba swallow";
var content_f15_48_16142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal esophageal stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow shows proximal esophageal stricture (arrow) due to reflux esophagitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Kahrilas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16142=[""].join("\n");
var outline_f15_48_16142=null;
var title_f15_48_16143="Four glass test";
var content_f15_48_16143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Four-glass test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnosis of chronic prostatitis is made by analyzing specimens obtained following prostatic massage. The periurethral area is cleaned and the patient allowed to void. The initial 5 to 10 mL (VB1) and a midstream specimen (VB2) are obtained for quantitative culture. The patient should stop voiding before the bladder is empty and the prostate should then be massaged. Any prostatic secretions that are expressed (EPS) should be cultured, as well as the first 5 to 10 mL of subsequently voided urine (VB3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_48_16143=[""].join("\n");
var outline_f15_48_16143=null;
